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(i)
ABSTRACT
Synthetic approaches to Endothiopeptides where the thioamide 
group has replaced the normal amide link are discussed and investigated,
A range of N-protected dipeptide esters (21) has been thionated 
exclusively, and in high yield, at the amide carbonyl using Lawesson's 
reagent (25) giving synthetically useful protected endothiodipeptides 
(55). Investigation of more conventional peptide methodology and its 
application to these new systems has been carried out.
Deprotection of the N-terminus of the endothiodipeptides (55) 
gives, after coupling, larger tripeptides with a single thioamide link. 
Extension of the C-terminus is achieved using the phenyl ester as an 
active ester group, thus avoiding a deprotection step. In this fashion 
the protected pentapeptide Z-Tyr(Bzl)-Glyt-Gly-Phe-Leu-OMe (87) has 
been prepared by two routes and represents a monothionated leucine 
enkephalin analogue. The fully deprotected pentapeptide (83) has been 
obtained via an alternative derivative, BOC-Tyr(BOC)-Glyt-Gly-Phe-Leu- 
OBu^ (94) in a single step, and may have greater and longer lasting 
analgesic activity than its normal oxygen counterpart.
Approaches to the synthesis of novel endothioaziridine peptides 
are explored. Milder thionation methods are needed to obtain these 
systems owing to the nature of the aziridine ring. Several direct 
thionation methods and indirect methods for incorporation of the 
thionation functionality are investigated.
(ii)
NOMENCLATURE AND ABBREVIATIONS
Chiral amino acids are of S stereochemistry unless otherwise 
stated. Amino acid and protecting group abbreviations are those 
recommended by lUPAC.^^^ The thiocarbonyl derivative is designated 




Phet = -N H
S
Other abbreviations used in the text are as follows:












FAB Fast Atom Bombardment
IPA Iso-propyl alcohol
IR Infra Red




n.m.r. Nuclear magnetic resonance
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Appendix : Publication of Results
I N T R O D U C T I O N
2.
1.1. BACKGROUND
The understanding of the mechanisms of pain and thus its treat­
ment has been one of the earliest medicinal and pharmacological 
objectives. A large number of pain relieving (analgesic) drugs are 
known of which morphine (1) is probably still the most important and 





Morphine acts on the central nervous system (CNS) unlike the 
"peripheral" antiinflammatory analgesics such as acetylsalicylic acid 
(Aspirin). The medicinal chemistry, pharmacology and toxicology of 
morphine and related compounds have been extensively studied.^
An essential feature of medicinal chemistry is the development 
of drugs with improved efficacy and less undesirable side effects.^
A wide range of morphine analogues have been synthesized, tested and, 
in some cases, marketed, for example dihydrocodeinone (Trade Names, 
Codone, Dicodid) (2) and Naloxone,^ (3).
Despite the extensive research in this area^ it is doubtful 







Standard against which other compounds are measured. Due to its 
serious side effects, however, it is restricted mainly to patients 
with severe pain.^
In Man morphine acts in a narcotic fashion, inducing analgesia, 
drowsiness, changes in mood (euphoria and dysphoria) and mental 
clouding. Minor side effects are constipation and pupil constriction 
but more serious drawbacks are respiratory depression, vomiting, nausea 
and, after prolonged use, drug tolerance and addiction.^ Although 
these side effects may be as a result of the opiate mode of action 
(through the CNS) there is clearly a need for a non-addictive, centrally 
acting analgesic with little or no side effects (’. ) but as yet none 
has emerged.




Met-enkephalin (4) Tyr-Gly-Gly-Phe-Met 61-65

















The Enkephalins (4 and 5) are endogenous pentapeptides with 
opioid properties. They belong to a class of neuropeptides found in 
the brain called the Endorphins which are (mostly) structurally 
related to a specific peptide sequence of the pituitary hormone 
3-lipotropin (Table 1).**
The opioid peptides show similar pharmacological effects to the 
morphine alkaloids. They act as inhibitory neurotransmitters affecting 
acetylcholine and norepinephrine release.** Their analgesic effect, 
however, is short lived presumably due to inactivation within the 
brain by 'peptidase* enzymes (see later). The control of many other 
nervous system functions are mediated by the endorphins. They can act 
as inhibitors and modifiers of pleasure, sleep, sexuality, eating and 
drinking, and also in the autonomic control of other body functions 
(i.e. blood pressure and respiration).***®
The enkephalins were the first opioid peptides to be isolated and 
structurally elucidated. This was achieved by Hughes et al.® (1975) 
after a search by other groups.^ The rationale behind this research 
stems from the conclusion that morphine itself must interact with 
specific brain receptors.^*^ *® ®  For instance, of all the morphine­
like compounds, with similar clinical effects, there are several 
common structural features present. These include an aromatic ring 
and a basic nitrogen atom at a distance from it of 2-3 carbon atoms. 
Small structural alterations lead to a dramatic decrease in activity. 
Morphine analogues can also antagonise its a c t i o n , f o r  example 
Naloxone (3).^^ Such antagonists probably interact with the same 
receptors as morphine in order to cancel or partially block its action. 
Receptors of this type must have been designed to interact with
6.
compounds other than morphine since most animals do not come into 
contact with opium poppies (I)
The enkephalins (and endorphins) have been shown to interact 
with similar receptors^^ and there are clear structural similarities 
between the tyrosyl amino acid (6) in the enkephalins and the 




In addition it is probable that the enkephalins can assume a conforma­
tion at the receptor(s) that closely mimics the rigid morphine-like
structure. 1 3
The important twin bioassays used to assess morphine for opiate 
activity in novel, potential analgesics are the Mouse Vas Deferens 
(MVD) and Guinea Pig Ileum (GPI) tissue preparations.^** The tissue is
7.
electrically stimulated and the depression of the contractions by 
opiates is measured. The two preparations have been shown to contain 
a mixture of r e c e p t o r s ^ ^ ^  and the enkephalin activity in these two 
systems, controlled by specific receptor interactions,^ i s  different 
due to the non-identical nature of the receptor populations. In the 
MVD case the enkephalins interact with "6-receptors" predominantly 
but also affect the "y-receptors" to a lesser degree. Conversely in 
the GPI system the opioid peptides interact with "y-receptors" and 
their activity is much less. Thus, it seems that "morphine receptors" 
are of the so-called y-type whereas "enkephalin receptors" are the 
6-type. From this one would expect morphine and analogues to be more 
active in the GPI assay while the enkephalins should be more potent in 
the MVD test and this is indeed the case.^® Other receptors (a,
K and e) have also been proposed as being implicated in opiate 
and enkephalin binding activity.^®
1.3. ENKEPHALIN ACTIVITY AND "ENKEPHALINASES"
Although many enkephalin analogues have been synthesized and 
assessed in vitro^ and their interactions with specific
receptors studied,^* their in vivo biological activity is short-lived. 
This may be attributed to poor passage through the blood-brain barrier^® 
and their susceptibility towards enzymic degradation after administra- 
tion?i*^2 All but one of the amide bonds in leucine or methionine 
enkephalin may be hydrolysed enzymatically^^ (Figure 2).
The most important sites of enzymic action are the Tyr-Gly amide 
link (although it has been suggested that this is not important in the 
inactivation of enkephalins at the synaptic c l e f t s ^ a n d  the Gly-Phe 




T Y R -G L Y -6 L Y -P H E -L E U
Aminopeptidase Angiotensin Converting Enzyme (ACE) 
(in vitro only) 
Dipeptidylcarboxypeptidase
(Enkephalinase A)
not been as well characterized as the other sites. Clearly, the 
development of more in vivo active enkephalin analogues requires 
improvement of their enkephalinase resistance without altering the 
specific receptor a c t i v i t y . 23 Alternatively the synthesis of 
inhibitors, or substances that will bind to the enzyme’s active site 
irreversibly ("suicide substrates") has also been carried out.^^
Based on analogy with the action of Carboxypeptidase Â ** (CPA) 
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bond
The development of successful inhibitors of Angiotensin 
converting enzyme (ACE) based on a similar model has led to the anti­
hypertensive agent Captopril (7 )2 *tb,2 5 other inhibitors based on
by-product analogy have also been studied (for example, L-benzyl- 
succinic acid^^). A related model may exist for the Gly-Gly bond 
cleavage case ("Enkephalinase" B ) .
Carboxypeptidase A which is a related enzyme to the dipeptidyl 
Enkephalinases A and B, in that it is a zinc containing enzyme 
operating on peptide amide bonds, has been proposed as having two 
major probable mechanisms of a c t i o n . T h e s e  are shown below in 












For both schemes binding to the zinc atom of the enzyme serves to 
polarize the scissile amide bond and may also twist it out of plane. 
Both these effects make it more susceptible to attack by nucleo- 
philes.^^^'^* In Scheme 1 the glutamic carboxylate group (present on 
the enzyme active site) promotes the attack of a water molecule on the 
amide bond giving a tetrahedral transition state. Abstraction of a 




























Glu CO^H -C O , NH —
HO-Tyr
12.
to amide bond cleavage.
For the second scheme, the glutamic carboxylate moiety again 
plays a prominent role. Attack on the polarized amide bond gives an 
anhydride type tetrahedral transition state. Following a similar 
path to Scheme 1, this cleaves to an acyl-enzyme intermediate (which can 
be later attacked by a water molecule giving two separate carboxyl 
groups) and the free amino peptide.
Both mechanisms have points in their favour but further studies 
are necessary to resolve the ambiguity. It may be that different 
substrates are cleaved according to different mechanisms.^* The main 
features of both are shown in Scheme 3.
Any functionality at the scissile position that can coordinate 
ffiofe strongly than oxygen may irreversibly bind to the enzyme. This is 
probably the case for Captopril, (7), and ACE. The potent enkephalinase 
inhibitor Thiorphan, (8 )* ((DL)-3-mercapto-2-benzylpropanoylglycine) 





Other functional groups required for activity in the enkephalins 
also fit the active site m o d e l . F o r  example the phenyl ring of the
Scheme 3
N H -











ENZ N H ,
phenylalanyl amino acid is accommodated in a hydrophobic "pocket” of 
the enzyme. The anionic carboxylate group interacts with an 
oppositely charged amino acid (possibly arginine).
These features would need to be present in any potential 
inhibitor for it to be "recognised" by the enzyme. Thus a molecule 
containing the minimum structural features necessary to obtain 
enzymatic resistance without losing pharmacological activity and/or
14.
receptor specificity^®^ would be the desired compromise. Other 
enkephalin analogues with these characteristics have been investigated. 
For example, the incorporation of specific dehydroamino acids into the 
enkephalin sequence at certain positions has produced analogues that 
are resistant to enzymatic h y d r o l y s i s . *^®® Although these analogues 
are hydrolysed slowly by carboxypeptidase enzymes in vitro and have 
high 6-receptor specificity, enabling the enkephalin receptor-substrate 
interactions to be more fully explored, their analgesic effect is 
weak. Possibly, this is due to their high 6-receptor activity, i.e. 
the analgesic effect may be more strongly mediated through the 
y-receptors.^®^ The concept of one receptor producing a specific 
response is difficult to substantiate although one receptor may be more 
responsible for one effect rather than another.*®
1.4. ENDOTHIOPEPTIDES
1.4.A Amides and Thioamides
The selective replacement of amide bonds by the thioamide*^ 
moiety which is expected to have similar steric and electronic 
requirements to its oxygen counterpart may have the desired effect 
of combining enzymatic resistance with analgesic activity. Coordination 
of the thioamide sulphur atom to the metal (zinc) could lead to more 
efficient substrate-enzyme binding (the affinity of sulphur for 
divalent metal cations is well known*^) yet the common structural 
requirements could equally yield analgesic potency. Furthermore, 
attack at the thiocarbonyl group will produce a tetrahedral inter­
mediate, orders of magnitude more stable than that for the natural 
substrate, and a relatively stable tetrahedral transition state 
surrogate could be formed.
15.
X-Ray s t u d i e s * h a v e  shown that the atoms of the thioamide 
bond are in a plane and spaced rather like an olefinic bond with bond 
angles of ~120°. The larger covalent radius of sulphur (1*04 x 10” ^®m) 
compared to oxygen (0*74 x 10” ^®m) means that the carbon-sulphur bond 
in thioamides (1*7 x 10” ^®m) is longer than in ordinary amides 
(1*25 X 10” ^®m) but the length of the carbon-nitrogen bond is about 
the same.*^^
Both the carbon-sulphur and carbon-nitrogen bonds are inter­
mediate in length between single and double bonds (Table 2). This




C-S 1*81 1-60 1*7 (1*24)
C-N 1*47 1*27 1*35 (1-34)
suggests appreciable electron delocalization (9 a) and much sp^ 
character in the carbon-nitrogen bond (in the valence bond theory this 
is analogous with the charged species (9c)).
(9q ) ( 9 b )  ( 9 c )
16.
The energy of activation needed for rotation about the carbon- 
nitrogen bond is greater in thioamides than that in a m i d e s . T h e  
non-equivalence of alkyl groups attached to nitrogen and the existence 
of conformational bias in thioamides has been established by n.m.r. 
techniques. Generally the %-isomer predominates aiAcl *̂ cr
'C —  N
^  \ p  R ^ > R 3s  R3
E-isomer
secondary thioformaraides dipole moment considerations have
been used to explain the Z-isomer preference.* The larger steric 
bulk of the sulphur atom means that the Z-isomer is generally 
less favoured for thioamides than for amides.
Two mesomeric forms for thioamides have been suggested (9b and 
9c). The thioimidate form (9c) is proposed on grounds of chemical 
reactivity and increased acidity of thioamides compared to amides. 
However, there is no or little spectroscopic evidence for its 
existence. X-Ray diffraction and fluorescence, n.m.r., IR and UV tech­
niques have shown no evidence for the imidothiol form*^^ and clearly 
there is insufficient of it present to allow detection by these 
techniques.
I.4.B. Literature review
Surprisingly, until recently the chemistry and synthesis of 
endothiopeptides** had not been extensively explored. The earliest
17
report of their synthesis is by Ried and von der Emden and by the 
same authors in 1961,^®and these reports had not been followed up. 
Their route to endothiodipeptide acids is shown in Scheme 4.
Scheme 4
XR^NH'^^^CN (10 ) a ; R,= Z . Rz= H
















a, R3OH, HCl; b, K 2C O 3 ; c, HgS, 18 h, RT; d, NaOH, glycine.
18.
N-Protected a-aminonitriles, (10), obtained via the Strecker 
synthesis^® from the aldehyde, hydrogen cyanide and ammonia, then 
N-protection, were converted to the amino acid imidoester hydro­
chlorides (11)3^ with ethanolic hydrochloric acid. Thionation with 
hydrogen sulphide, after desalting with potassium carbonate, at room 
temperature (18 h) gave the key intermediate N-protected a-amino acid 
thionoesters (12). The latter were successfully coupled to other 
amino acids by sodium hydroxide treatment. Four examples of N-protected 
endothiodipeptide acids, (13), were prepared in this way.
Subsequently Ried and Schmidt^® (1966) tried a different route to 
obtain the thionoesters (12) whereby the N-protected amino acid amide 
(14) (obtained from the acid chloride via ammonia treatment) is 
refluxed with triethyloxonium tetrafluoroborate giving the salts (15) 
(Scheme 5).
This route used enantiomerically pure amino acid amides in some 
examples but no assessment of the optical integrity of the product(s) 
is made. An improved route to (12) was tried and the final step 
utilized triethylamine (TEA) rather than sodium hydroxide as a base. 
Although yields were moderate-to-good both routes used inconvenient and 
hazardous reagents (hydrogen sulphide), several steps and prolonged 
reaction times and thus accentuated racemization problems.
More recently Mock et aJ.®® (1981) and Campbell and Nashed^® (1982) 
prepared the tripeptide (19) (Scheme 6 ) but used the dithioester (17) 
instead of the thionoesters (12) used by Ried and co-workers.®^*®®*®® 
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a, EtgO BF\, A, DCM, 0-75 h; b, TEA; c, HgS, 8  h; d, TEA, amino 
acid, RT, 24 h.
Scheme 6
20.
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Although experimental details are brief one can envisage several 
steps in order to obtain (17)**^ and the coupling reaction requires a 
lengthy reaction time. The tripeptide free acid (20) was found to be 
much more slowly hydrolysed (over 1 0 0 0  times), than its oxygen analogue, 
by Carboxypeptidase
In the last few months other a u t h o r s h a v e  in fact extended the 
dithioester approach to the synthesis of the four possible modified 
enkephalins. Other endothiopeptides^^ have also been synthesized by 
this method and direct thionation methods. However, this work will be 
discussed more fully later (Results and Discussion).
21.
I.4.C. Thionation Methods
Thus, it would be desirable to devise a short (preferably one- 
or two-step) route to endothiopeptides. The logical method involves 
direct thionation of N-protected dipeptide esters (21).
0II N H O RN HR . 0
(21 )
Once thionation of the amide bond has occurred deprotection at the 
amino or carboxyl terminus should allow access to larger systems.
Although methods of preparation of thioamides are well known 
(Table 3)^^ direct thionation via phosphorus pentasulphide usually 
involves an excess of the reagent, prolonged reaction times and/or 
elevated temperatures. Additionally there is the problem of regio- 
selectivity in substrates of type (21). High temperature reaction 
conditions involving an excess of phosphorus pentasulphide could 
lead to polythionation of the carbamate, amide and ester carbonyl 
functionalities in (2 1 ) and presumably for some of these reasons the 
direct thionation method was reported as unsuccessful.^^ Other methods 
outlined in Table 3 include the problems associated with the work of 
Ried et i.e. several steps and rather drastic conditions.
Recently, however, several milder methods of thionation have 
been developed with phosphorus p e n t a s u l p h i d e , u s i n g  ultrasonica- 
tion to improve the homogeneity of the reaction and hence lower
22.
Table 3 General methods of Thioamide formation (pre 1978)
Starting material(s) Product(s)
HgS ) TEA f\
R C N   ►
A or P
0 s11 P j S 5 , A  H
R - ^ ^ N R ;   *- R - ' ^ N R .
NR
II
R - '^ C I   ► R^ ^NHR
l
N R  S S
" HjS M J J
R ^ ^ N H R   ► R ^ ' ^ N H j  or R  N H R
0
Il S ; , R N H ;
R ^ ^ ^ M e   ►  R  II
A S
P y S R




reaction times and temperatures**** and also, in combination with 
triethylamine and a polar solvent such as acetonitrile where a charged 
species (2 2 ) is possibly involved.**^
P, S , - N E t 3
(2 2 )
Additionally, a novel mild thionation method has been success­
fully used on simple substrates with the in situ formation of boron 
trisulphide (B2S 3 ) from Bis(tricyclohexyltin)sulphide and boron 
trichloride.**® This method is claimed to operate under neutral 
conditions although the use of boron trichloride may cause problems 
with substrates of type (2 1 ) where the amino and carboxyl protecting 
groups are Lewis acid sensitive (e.g. tert-butoxycarbonyl). A facile 
way round this problem would be to preform the boron trisulphide and 
then add the substrate. These methods deserve further investigation 
applied to peptide substrates although the phosphorus pentasulphide/ 
triethylamine system has been used to obtain the single endothiodi­
peptide (23) . **̂  This was deprotected at the carboxyl end via alkali 
treatment to give the free acid which was a mild, competitive inhibitor of 
Carboxypeptidase A. Although the endothiodipeptide bound to the 
enzyme at a comparable rate to its oxygen analogue it.was hydrolysed 
at only 10% of the rate. This may reflect the degree to which the 
enzyme-substrate tetrahedral transition state is irreversibly bound. 
This however was the only example studied.
0 
II
Z N H ^  ^  ' ^ O M e  ( 2 3 )
Ph
24.
More recently, phosphetane disulphides (24)**® have been utilized 
as thionation agents.
( 2 4 )
The conversion of carbonyl compounds to their thiono-derivatives using 
2 ,4-bis(4 ’-methoxyphenyl)-!,3-dithia-2,4-diphosphetane-2,4-disulphide, 
(25) (Lawesson’s reagent) proceeds in high y i e l d s * * ® a n d  specifically
( 2 5 )
thioamides have been prepared from amides.® ^ ® ®  Prior to the 
beginning of this programme (25) had not been used for the thionation 
of peptide substrates.®** The efficiency of the reagent in other 
systems warrants its application to suitably protected dipeptide sub­
strates ((25) is known to react with the amino and carboxyl 
functionalities®^). Regioselectivity of thionation was unknown 
(amide vs carbamate vs ester carbonyl) although based on literature 
precedent®® the ester carbonyl was expected to be the least reactive.
Further, more subtle regiochemical control where several amide 
bonds are present, in higher peptides had not been explored. To what 
extent does the amino acid side chain (R2 ,R3 in (2 1 )) influence the 
thionation? Modification of the original reagent, as follows in (26)
25.
and (27), may allow greater reactivity and/or selectivity, especially 
in (26) where steric crowding may allow this reagent to differentiate 
between amide bonds. It would be desirable to selectively thionate a 
specific amide link in higher peptides which would give rapid access 
to larger systems with one thioamide bond p r e s e n t . T h e  latter 
approach may have severe limitations, however, where a Gly-Gly
S g __
( 2 5 )  
R ^ S
S  s  ( 2 7 )
s s
27a,  R = P h
dipeptide link is present if it is desired to thionate a different, 
more crowded, amide bond in the molecule. Being much more sterically 
less hindered, the Gly-Gly bond will probably always thionate in 
such a case.
I.4.D. Racemization
It is evident that more conventional peptide chemistry (coupling, 
protection, deprotection methods) will have to be used to surmount the 
latter problem. To what extent are these techniques applicable to the 
new systems? Racemization is also a key issue in peptide chemistry and 
the effect of (25) on the stereochemical integrity of amino acid chiral
26.
centres was unknown. If thionation occurs selectively at the amide 
bond will the more nucleophilic sulphur atom cause scrambling 
(racemization) of the stereocentres in subsequent deprotection and 
coupling steps?
A cause of racemization in conventional peptide chemistry is the 
formation of 2-oxazol-5-ones (29) from active esters of acylamino 
acids (28)5^ (Scheme 7).
Scheme 7
R






( 2 9 )
R,
G ----
( 2 8 ) R;
0
X =  OR3 or N H R ,
The presence of base in the reaction mixture causes proton abstraction 
and a "5-exo-trig" intramolecular ring closure with loss of the active 
ester species. Enolization of the oxazolone causes racemization once 
the ring (29) is reopened by alkoxide or by the free amino component
27.
present in the reaction. The resultant dipeptide has racemized.
This problem is usually circumvented firstly by the use of 
alkyloxycarbonyl amine protective groups, which do not form 
oxazolones as readily and for which the corresponding alkyloxyoxazolones 
have a far less acidic proton than their alkyl counterparts (from 
acylamino p e p t i d e s ) , o r  secondly by the use of reaction conditions 
that do not accentuate oxazolone formation^® (i.e. base equivalence, 
low temperatures, low polarity solvents).
For the thioamide analogues a similar problem may arise in 
dipeptide substrates (21) by the formation of 2-thiazol-5-ones, (30), 
(Scheme 8 ) and their tautomerism with the "enol" (31).
Scheme 8
0  R .













The extent of this potential problem in endothiopeptides is as yet 
unknown. 2-Thiazol-5-ones (30) formation can also be envisaged as 
occurring from the N-protected endothiodipeptide acids (13) via the 
dehydrative effect of DCC in coupling reactions.^® This may alter the 
rate of reaction dramatically to adverse effect.
1.5. ENDOTHIOAZIRIDINE PEPTIDES
The reactions of endothiopeptides may allow novel and efficient 
access into other biologically interesting targets. Recently, a 
number of cyclic peptides with active anti-microbial and neurophysio- 
logical properties have been isolated from marine sources.®®” ®^ Many 
of these contain the thiazole amino acid unit (32) in an alternating 
arrangement either with other amino acids or with 2-oxazoline acids 
(33).
—  H N
( 3 2 )
R  0







Ascidiacyclamide, (34)®^ contains both these units and is a potent 
cytotoxic agent. Its synthesis and that of related analogues may 
produce pharmacologically useful molecules. A retrosynthetic scheme 
directed at this target is shown in Scheme 9.
The symmetrical nature of (34) means that it can be analysed into 
two dipeptide derived units (35) and (36) containing the thiazole and 
2-oxazoline moieties. The former may be envisaged as being obtained 
(via an aziridine isomerization, then oxidation) from the endothio- 
aziridine peptide (37). The latter systems are not known in the 
literature although the isomerization of acyl and thioacyl aziridines
30.
S c h e m e  9
(3 4)
NH OH
( 3 5 )
NH OH
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31.
has been investigated^** and reviewed.®^ The use of peptide systems 
like (37) for the preparation of thiazoles has not been explored 
although the attempted isomerization of aziridine containing peptides 
similar to (38) has been reported^^ using sodium iodide. Other methods 
for the conversion have not been tried but it is expected that (37) 
should undergo this isomerization more easily^^ than (38).
Both (37) and (38) are derivable from simple amino acids although 
the reactivity of aziridines towards thionation agents like (25) is not 
known. Other milder thionation methods (see previous discussion) may 
be necessary to convert (39) to the thioaziridine (37). The 
N-protected amino acids iso-leucine (40) and valine (41) are readily 
available. Suitable serine and threonine esters ((44) and (45)) are 
known to give the desired aziridines (42) and (43) although (42) is not 
well described in the relevant l i t e r a t u r e . B o t h  aziridines have 
been used by Japanese workers to obtain other peptide derivatives 
through stereo-controlled aziridine formation and ring opening (two 
inversions, net retention of configuration). For example, depsi- 
peptides,®® dehydroamino acids^° and cysteine peptides^^ have been 
derived from aziridines.
Previously more conventional routes into thiazoles and thiazole 
amino acids, including (35), have been r e p o r t e d . T h e  Hantzsch 
synthesis^^ involving the condensation of a thioamide (46) with an 
















X =  Hat
(48)
In this manner (35) has been prepared^^ in 6 steps via the Strecker 
synthesis^® of the appropriate a-amino nitrile (49).
(4 9 )
MeMe
No control of chirality is possible in this route because of the 
nature of the Strecker reaction.
Thiazoles (52) have also been obtained from amino acids (50) 
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cyclization of a-thbacylamino ketones (53). 73
(53)
However, the proposed .route has the advantage of being novel and 
exploring the hitherto unknown chemistry of endothioaziridine peptides.
2-Oxazolines (for example (36)) are generally prepared via a 







To make the route to Ascidiacylamide (34) strategically more convergent 
the isomerization of aziridine peptides to 2-oxazolines (so far 
unknown) is preferred.
1.6. CONCLUSION
The synthesis of endothiopeptides has not been fully explored 
and their biochemistry and pharmacological properties not investigated. 
Modifications of biologically important peptides (such as the 
enkephalins) with the thioamide functionality offer great potential.
A study of these systems may answer some questions, and raise others, 
about enzyme-substrate interactions and mechanisms.
R E S U L T S  A N D  D I S C U S S I O N
36.
2.1. THIONATION OF DIPEPTIDES
The initial purpose of this work was to develop a synthetic 
route(s) to peptides containing the thioamide functionality. Selective 
replacement of amide bonds in small peptides by their sulphur counter­
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A direct route to endothiopeptide systems has obvious advantages and 
the use of Lawesson’s reagent (25)**® as a thionation agent was 
e x p l o r e d . ® ^ U n p r o t e c t e d  dipeptides were not used as substrates 
since (25) has been shown to react with both amino and hydroxyl 
functionalities.®^ Additionally, the use of protected dipeptides 
should give greater flexibility because of the potential deprotection 
of either terminus after thionation. Thus, readily available N-alkyl- 
oxycarbonyl dipeptide esters (21) (Table 4 ) were thionated exclusively 
at the amide carbonyl in high yields (70-100%) using (25) (Scheme 12).
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Table 4 : Substrates and products of the thionation reactions
Substrate
(Product) Ri R® R*’
21a (55a) PhCHz H H CH3
/ — \
21b (55b) PhCHz H H C H 2 - ^  V o C H a
21c (55c) PhCHz H H
\  . _ V
Ph
21d (55d) Bu^ H H CH2Ph
21e (55e) PhCHz CHs CH3 CHa
21f (55f) PhCHz PhCH2 H CHa
21g (55g) PhCHz CH2CH(CH3)2 H CHa









No thionation was observed at the ester or carbamate carbonyl 
g r o u p s . '75 A summary of the endothiodipeptides ((55a-g) and (23))
38,
obtained is shown in Table 5. The products are rapidly formed and 
easily purified by column chromatography. A side product (56) from 
the thionation®^ *5**^ is easily separated from the desired products.
(56)
Ar = ^ OMe
The spectral data of the endothiopeptides ((55) and (23)) show 
obvious similarities with the starting materials (21). The n.m.r. 
spectra, however, show that the amide carbon is shifted downfield by 
about 30 ppm to -200 ppm. The ester and carbamate carbonyl signals 
remain the same. The methylene and methine carbons of the peptide 
backbone are also shifted downfield, by between 5 and 8 ppm, compared 
to the normal dipeptides.
The most notable difference in the n.m.r. spectra is the 
characteristic downfield shift (1*5-2*0 ppm) of the NH proton of the 
newly formed thioamide group. The carbamate NH proton is less 
affected by the transformation and the methylene and methine protons 
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The U.V. and I.R. spectra are also indicative of the thioamide 
functionality. The amide carbonyl stretching frequency at 1650 cmT^ 
completely disappears in the I.R. spectra of (55) and (23) while the 
U.V. spectra show a maximum absorption at 260-270 nm, characteristic of 
a n +  n* transition for the thiocarbonyl group.®^
To check that no racemization of the adjacent chiral centres had 
occurred in the thionation, a 400 MHz ^H n.m.r. spectrum of (S,S)-Z- 
Alat-Ala-OMe (55e) was obtained. The latter shows overlapping doublets 
(1*46 and 1*47 ppm, J = 7 Hz) of the methyl groups and pentets (4*6 and 
5*05 ppm, = 7 Hz) for the methine protons. The high signal
to noise ratio and sensitivity of the technique would allow detection 
of other diastereoisomers of >2% but no other signals were seen.
The conformational consequences of the introduction of the 
thioamide group were studied by differential n.O.e.^® spectra of (21e) 
and (55e). Each compound was similar in showing effects consistent 
with the favoured conformation(s) ((57) and (58)) where the amide (or 
thioamide) NH is hydrogen bonded to the carbamate carbonyl oxygen atom. 
For (55e) irradiation of the Ala^ methyl group produced an enhancement 
(33%) of the methylene proton signal which was non-existent in (21e). 
However, the latter showed instead an enhancement (14%) of the 
carbamate NH proton signal when the methylene group was irradiated. 
These results are consistent with the favoured conformations shown 
((57) and (58)).”
The thioamide proton is more acidic than the amide case which 
could lead to stronger hydrogen bonding in (57). The resulting 
depletion in electron density in the carbamate carbonyl may result in 
its C-0 bond having more double bond character favouring the different 
conformation (58) about the carbamate C-0 bond.
41.
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The mechanism drawn for the thionation reaction is speculative at 
this point. A possibility is shown below (Scheme 13) and may involve 
a cyclic intermediate (60) which decomposes, the driving force being 
P-0 bond formation.
Differences in the rate of thionation, for example between (21a) 
and (21g) were not observed. Although longer reaction times were used 
in some cases, most or all of the desired product was rapidly formed 
(within 1 h). Thus it seems unlikely that higher peptides could be 
selectively thionated at a specific amide link using Lawesson’s reagent
(25), although the possibility of using modified reagents (for example
(26) and (27)) in this fashion is not precluded.®® The use of moderate 
temperatures in this reaction is only necessary to achieve homogeneity 
since Lawesson’s reagent (25) is not readily soluble in most organic 
solvents at room temperature. It is possible that the thionation
42
Scheme 13
■ C n H \     \  ^ N H
0
C ) A
a N H \  \  / N Hx;
° \  ° N T y ^
a/"^S ' A/<>S
(60)
N H \  /
could be carried out at lower temperatures if a better solvent could 
be found. This may itself lead to greater selectivity.
Recent work by Lajoie et al,^^ has illustrated the possibility by 
using the modified reagent (27a). The greater solubility shown by 
(27a) allows the thionation to be carried out at room temperature or 
below and greater selectivity is achieved. Thionation of the least 
sterically hindered amide link is preferred. For example, glycine- 
glycine amide bonds are thionated preferentially in oligopeptides.
43.
27a ,  R =  Ph
However, this is a disadvantage in systems where the desired thioamide 
link is the more crowded one. In such cases conventional peptide 
coupling, protection and deprotection techniques'^ may be required to 
incorporate the thioamide functionality, via a stepwise or fragment 
coupling approach using simple endothiodipeptide systems such as (55).
A  range of protective groups is compatible with the thionation proce­
dure (Table 5) and their selective removal was next investigated.
2.2. DEPROTECTION METHODS
It was found that the endothiodipeptide Z-Glyt-Gly-OMe (55a) 
could be deprotected at the amino terminus using hydrogen bromide in 
acetic acid^® at room temperature (<0*25 h) giving the hydrobromide 
salt (61) in excellent yield (95%) (Scheme 14). The feasibility of 
synthesizing higher peptides by extending from the amino end was con­
firmed by the coupling of Z-Ala-OH (62) with the hydrobromide salt (61) 
using DCC/TEA giving the novel tripeptide Z-Ala-Glyt-Gly-OMe (63).
0
O H  (62)
0
P h '  ^ 0 - "  ^ N H
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a, HBr/AcOH, RT, 0-25 h; b, (62), DCC, -20°C, 0-25 h; c, (61), TEA, 
RT, 16 h.
A slightly different acidolytic cleavage procedure for removal of 
the tert-butoxycarbonyl amino protective group from Boc-Glyt-Gly-OBzl 
(55b) using TFA (90%)®° gave the trifluoroacetate salt (64). The 
thioamide group in both these examples was untouched by acidic 
reagents. Other workers®®^ have reported that thioamides are not 
stable to TFA but in our case no problems were observed.
45
(64) TFA.HjN
However, treatment of Z-Ilet-Gly-OMe (55g) with HBr/AcOH at room 
temperature (1*5 h) gave the free endothiodipeptide acid (65) under 
surprisingly mild conditions where both amino and carboxyl 
protective groups had been removed.
(65)
HBr.HgN
Methyl esters of N-protected peptides are normally not acid 
labile under these mild conditions.®^ Indeed the benzyloxycarbonyl 
(Z) amino protective group is commonly used because of its compati­
bility with, and selective cleavage from, the methyl ester group.®^ 
That the free acid had been obtained was conclusively demonstrated by 
its n.m.r. data. The spectrum of (65) showed a singlet at 4*45 ppm 
and a doublet at 4*05 ppm attributed to the methylene and methine pro­
tons (no coupling with NH because of proton exchange with solvent) of 
the peptide backbone. The methyl ester protons would be expected to 
resonate in the 3*5-4*0 ppm region but no signals were observed in 
this part of the spectrum. Other signals were as expected for an 
iso-leucyl containing peptide. The ^®C n.m.r. spectrum showed signals
46.
similar in chemical shift to starting material (55g) with two 
important exceptions. There was no methyl ester carbon signal at 
~52 ppm and the Z group signals had also disappeared. The thioamide 
carbon was present at 200*9 ppm.
It is difficult to account for the unexpected sensitivity of 
this dipeptide (55g) towards acidic conditions. The complete 
deprotection of Z-Glyt-Gly-OMe (55a) by HBr/AcOH required both a 
longer reaction time (6 h) and a higher temperature (50-60°C) to 
remove amino and carboxyl protective groups. The reaction gave a 
precipitate of thioglycyl-glycine hydrobromide salt (66) when ether 
was added to the cooled reaction mixture.
(66)
HBr.HgN
The I.R. spectrum of the product (66) showed a broad OH stretch 
at 2900 cm~^ and the disappearance of any carbonyl stretching 
frequencies above 1650 cm“ ^. A rather weak band was seen at 1620 cm”  ̂
attributable to the carboxylate functionality. The ^H n.m.r. spectrum 
showed the two methylene glycine protons as two singlets at 3*9 and 
4*1 ppm (all other protons exchanged with solvent). The mass spectrum 
of (66) gave a weak molecular ion at m/e 148 (M-HBr) and characteristic 
peaks at 130 (I4 8 -H 2O) and 114 (lOO-NHg).
The endothiodipeptide Z-Glyt-Phe-OMe (23) is a possible precursor 









It may be more active in vivo than the natural peptide because of its 
greater enzyme resistance. Conventional peptide techniques should 
allow the synthesis of this compound, starting with deprotection at 
either end of the dipeptide (23). Cleavage of the benzyloxycarbonyl (Z) 
amino protective group gave the hydrobromide salt (68) (79%). The 
latter was coupled to Z-Gly-OH (69) using a newly developed coupling 
agent®^ (diphenylphosphinyl chloride, DPPCl (70)) (Scheme 15).
DPPCl (70) rapidly forms a carboxylic-phosphinic mixed anhydride 
(72) with N-protected amino acids which is then attacked, regioselect- 




The side product from the reaction is diphenylphosphinic acid (73) 
which is easily removed by aqueous washing. This gave the endothiotri- 
peptide, Z-Gly-Glyt-Phe-OMe (71), the free acid of which could itself
Scheme 15
48,
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a, HBr/AcOH, RT, 0*5 h; b, (70), NMM, -20°C, 0-25 h then (68), NMM, 
16 h to RT.
be an inhibitor of carboxypeptidase (enkephalinase) enzymes.
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However, our attempts to deprotect the methyl ester by alkaline 
hydrolysis of the N-protected endothiopeptide esters (55) were only 
partly successful.
For instance, treatment of Z-Glyt-Gly-OMe (55a) with an equi­
valent of sodium hydroxide overnight®** gave a deeply coloured (orange) 
solution which after a standard work-up gave the free acid (13a) 
(Scheme 16) (55%) (^H n.m.r., MS) in an impure form.
A possible explanation for the moderate yield of product may be 
the formation of the sodium thioimidate (74).®® This may then further 
react intramolecularly to form the 2-thiazol-5-one (75;^76) with 
expulsion of methoxide ion. However, the latter compounds were not 
isolated from the reaction mixture.
Treatment of (71) in a similar manner gave, after an acidic 
work-up, a two component mixture which was separated by chromatography 
giving the free acid (77) (60 MHz ^H n.m.r., TLC) (60% yield).
Z N H
(77)
A trial experiment on a small amount of (71) using HBr/AcOH to 
effect deprotection of the benzyloxycarbonyl protective group gave what 
appeared to be the doubly deprotected tripeptide (78) instead of the 
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The enhanced reactivity of (71) towards acidic reagents is 
difficult to explain but has been also observed with Z-Ilet-Gly-OMe 
(55g). In view of these only partly successful results and because of 




work on the tripeptide, Z-Gly-Glyt-Phe-OMe (71) was curtailed. Although 
methods of carboxyl deprotection via alkaline hydrolysis of N-protected 
endothiopeptide esters were possible, other carboxyl protective groups 
were investigated.
2.3. USE OF THE PHENYL ESTER PROTECTING GROUP
Ideally, an active ester group®^ would allow coupling at the 
carboxyl end without prior deprotection. The 4-nitrophenyl ester 
group has been used in this fashion.®^ However, an attempt to 
thionate Z-Gly-Gly- ONp (80)®® using Lawesson’s reagent (25) was 
unsuccessful (Scheme 17).
This reaction afforded several inseparable, unidentified 
products. Significantly, a small amount of 4-nitrophenol (82) was 
obtained from the reaction so that thionation possibly resulted in
Scheme 17
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(80) Z N H
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an intramolecular cyclization whereby the 4-nitrophenate anion was 
displaced by the thiono group (Scheme 17) giving the 2-thiazol-5-one 
(75). Although the latter compounds have been implicated in several 
reactions of endothiopeptides so far in this Thesis, their involve­
ment has not been clearly demonstrated.
The use of the phenyl group of, for example, Z-Glyt-Gly-OPh (55c) 
as an active ester is also feasible.®^ The phenyl ester should be 
displaceable by an amino acid or dipeptide, albeit in a less facile
53.
manner^° than usual active esters. The dipeptide (55c) is thus a 
potential precursor of the leucine enkephalin analogue H-Tyr-Glyt-Gly- 
Phe-Leu-OH (83) (Scheme 19).
OH
NHNH, NH OHNH NH
(87)
As a trial reaction to test this presumption, the tripeptide 
Z-Glyt-Gly-Gly-OMe (84) was prepared from (55c) and glycine methyl 
ester hydrochloride (85) (Scheme 18).
A refluxing solution (2-propanol) was required to effect the 
reaction in a short time. Displacement of phenol by the glycine 
residue gave the tripeptide (84) in moderate yield (47%). This 
represents the replacement of the first amide bond of a tripeptide by 
its sulphur analogue (cf (63) and (71)) where the second amide group 
was replaced). Although the yield is only moderate, the reaction is 
comparable with the two step sequence represented by alkaline hydroly­
sis of the dipeptide (55a) (55%) followed by coupling (using, for 
example, DPPCl) with glycine methyl ester (85) (which would be ~90%). 
Since the phenyl ester appeared to be a suitable, albeit fairly 



















a, TEA, 2-propanol, A, 8*5 h.
2.4. SYNTHESIS OF H-Tyr-Glyt-Gly-Phe-Leu-GH (83)
2.4.A. [4+11 fragment synthesis of Z-Tyr(Bzl)-Glyt-Gly-Phe-Leu-OMe (87)
As previously mentioned, the dipeptide Z-Glyt-Gly-OPh (55c) is a 
suitable, readily available precursor of the target monothionated 
enkephalin (83).
Coupling of (55c) with the hydrochloride salt of the dipeptide 
H-Phe-Leu-OMe (88) was carried out following a similar method to that 
used for Z-Glyt-Gly-Gly-OMe (84) and gave the tetrapeptide 
Z-Glyt-Gly-Phe-Leu-OMe (86), albeit in slightly poorer than expected 
yield (43%) (Scheme 19).
55.
Scheme 19 : [4+11 route to Z-Tyr(BzD-Glyt-Gly-Phe-Leu-OMe (87)
(21c) Z — G ly —G I y - O P h
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a, (25), 80-90°C, 1 h; b, (88), TEA, 2-propanol, A, 2*5 h; 
c, HBr/AcOH, RT, 0-5 h; d, (89), (70), NMM, -20°C, 0*5 h then (90), 
NMM, RT, 16 h.
H -  Phe- Leu-OMe ( 8 8 ) Z-Tyr(Bzl)-OH ( 89)
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All spectral data for (86) were in accord with its structure.
The n.m.r. spectrum (400 MHz) showed signals indicative of a peptide 
containing phenylalanyl, leucyl and glycyl amino acid residues. In 
addition, a broad singlet (IH) was seen at 9*05 ppm, the characteristic 
low field value of the thioamide proton.
The n.m.r. spectrum (Figure 4) showed four carbonyl signals 
between 156 and 173 ppm due to the carbamate, amide (2) and ester 
groupings. The thioamide carbonyl appeared at 200*1 ppm consistent 
with previously described di- and tripeptides.





a 126*2-137*6 i 40*3
b 65*8 j 171 (172*6)
c 156*0 k 50*4 (51*3)
d 51*7 1 40*3
e 200*1 m 24*2
f 47*6 n 21*3 and 22*7
g 172*6 (171*0) o 166*7
h 51*3 (50*4) p 53*7
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The FAB (+) mass spectrum of (86) showed the protonated molecular
ion (m/e 557) with intense signals at 293 (Phe-Leu-OMe fragment), 146
+
(Leu-OMe) and 120 (HzN^CHCHzPh).
Deprotection of the tetrapeptide (86) by HBr/AcOH at room 
temperature (0*5 h) gave, after column chromatography, an almost 
colourless oil, which was, tentatively (at this stage), identified 






An explanation for the lower than expected yield was supplied by the 
isolation of the dipeptide (88) (H-Phe-Leu-OMe) from the reaction 
mixture (Scheme 20). This obviously results from cleavage of the 
Gly-Phe bond and may have been as a result of protonation followed by 
intramolecular cyclization of the thiono group. The 2-thiazol-5-one 
structure (75) was not, however, proven (Scheme 20).
The putative tetrapeptide (90) was next coupled to 
Z-Tyr(Bzl)-OH (89) using the DPPCl/NMM method.®^ This gave the 













H — P h e -L e u —0 Me 
(88)
The n.m.r, (400 MHz) signals for (87) are shown in Figure 5. 
All the assignments are as expected for a peptide of this nature except 
for the thioamide NH proton which is at a relatively low field value 
(9-7 ppm).
Figure 5; chemical shifts of (87)
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a 4*95, 4*91 
b 7-55 
c 4*27 






j 8*35 or 8-38
k 4*21 or 4*59
1 3-04, 2-75
m 8 • 35 or 8 • 38
n 4-21 or 4-59
o 1-44— 1-46 
p 1-44-1-46 
q 0-91, 0-94 
r 3-60
In addition the I.R. spectrum showed three carbonyl stretching 
modes at 1740 (ester), 1700 (carbamate) and 1655 cm  ̂ (amide) and the 
U.V. spectrum a maximum absorbance at 267 nm, consistent with 
previously described thioamide containing peptides.
Although this route gave the protected target compound, we were 
dissatisfied with several aspects of the approach. Clearly the 
deprotection of the tetrapeptide (86) may be an example of a problem
60.
for the synthesis of endothiopeptides in general where a benzyloxy­
carbonyl protective group and HBr/AcOH are used in conjunction.
Although the key coupling reaction gives only a moderate yield, this 
was felt to be satisfactory enough for the purpose.
As an alternative, a second approach using a [3+2] fragment 
coupling was investigated.
2.4.B. [3+2] fragment synthesis of (87)
Deprotection of the starting dipeptide (55c) using the familiar 
HBr/AcOH conditions^® gave the hydrobromide salt (91) (Scheme 21). The 
latter was identified by its ^H n.m.r. and I.R. spectra and its 
structure confirmed by coupling with Z-Tyr(Bzl)-OH (89) using DPPCl/NMM 
to give the novel tripeptide Z-Tyr(Bzl)-Glyt-Gly-OPh (92) (in overall 
88% yield from (55c)) (Scheme 21).
This compound was poorly soluble in most organic solvents which 
made large scale purification rather time-consuming. However, the 
clean coupling reaction made chromatography unnecessary on most 
occasions. In common with other tripeptides with a single thioamide 
link ((63), (71) and (84)) Z-Tyr(Bzl)-Glyt-Gly-OPh (92) has three 
carbonyl signals in its ^®C n.m.r. spectrum (157-172 ppm) and the 
thiocarbonyl carbon at 201 ppm. The ^H n.m.r. spectrum again showed 
the thioamide NH proton at a relatively low field value (9*7 ppm).
Having obtained the left-hand segment of the required target 
in this convergent approach, the next coupling step with (88) was 
carried out as described previously (refluxing 2-propanol, TEA) but 
gave a poor yield (29%) of the desired protected pentapeptide (87). 
Yields were consistently only 25-35% in this reaction, although a 
higher yield (50%) was obtained on one occasion. The pentapeptide
Scheme 21 : [3+21 route to (87)
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0
(91) H B r .  HgN NH OPh
(92)
(87)




OMeNH NHNH NHZ N H
a, (25), 80-90°C, 1 h; b, HBr/AcOH, RT, 0-5 h; c, (89), (70), NMM, 
-20 C, 0*5 h then (91), NMM, RT, 16 h; d, (88), TEA, 2-propanol
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(87) was identical to that obtained by the [4+1] route (Section 2.4.A.).
This route circumvents the problems associated with the 
deprotection of (86) but gives a low yield in the last step. However, 
the overall yield from Z-Gly-Gly-OPh (21c) is 18% for the [3+2] route 
(compared to 8% for the [4+1] approach) and is preferred since only the
last step is a poor one.
The phenyl ester peptides ((55c) and (92)) are only moderately 
reactive^® and for this reason a slight excess of TEA and higher 
temperatures were used to achieve shorter reaction times. Where the 
C-terminal amino acid is glycine (as here) this clearly is unimportant. 
However, an excess of tertiary base in peptide coupling reactions is 
generally not desired^^**^ since racemization via the intermediate 
2-oxazol-5-ones (29) can occur. In the endothiopeptide case a similar 
problem could be envisaged (where the C-terminal amino acid is not 
glycine) via the speculative 2-thiazol-5-ones ( 3 0 ) . Although no work 
has been carried out on this potential problem it may be overcome by
using the free amino component instead of its salt (thus avoiding any
tertiary base) although the reaction times may be lengthened by this. 
Another way round the problem would be to increase the reactivity of 
the phenyl esters by the addition of an equivalent of acid^^ and hence 
carrying out the reaction at room temperature. This has not been tried 
in this work due to lack of time but no particular problems are 
foreseen.
2.4.C. Attempted deprotection of Z-Tyr(Bzl)-Glyt-Gly-Phe-Leu-OMe (87)
With the title compound in hand we turned to its deprotection and 
in this regard were unsuccessful. Several reactions were tried on a 
small scale (50 mg) to assess the reactivity of (87) towards various 
common deprotection reagents.
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Treatment with trifluoroacetic acid (TFA)®° or with a combination 
of TFA and trifluoromethanesulphonic acid (TFMSA)®^ gave a mixture of 
components by TLC and there was also evidence of the dipeptide 
H-Phe-Leu-OMe (88) in the TFA case.
A solution of boron tribromide in DCM^** and also in combination 
with TFAf^ has also been used to effect removal of most protective 
groups. However, in our case only a slow reaction was obtained using 
the reagent with DCM/dimethylacetamide (necessary to dissolve the 
pentapeptide (87)). An initially more promising result was achieved 
using a boron tribromide /DCM solution with the minimum amount of TFA 
necessary to dissolve (87). All of the starting material was consumed 
after warming to room temperature (from -10°C) (2*5 h) and four 
components were separated by preparative paper chromatography. However, 
the mass spectral data on the main component (5 mg) was not conclusive; 
the only significant ion seen was at 261 m/e which may indicate the 
dipeptide H-Phe-Leu-0H(-H20). The minor components (<10 mg) were not 
pursued.
In an attempt to remove the methyl ester group of (87), alkaline 
hydrolysis with sodium hydroxide ( 1 *09 equivalents) was carried out.®** 
Some pentapeptide was still present after the duration of reaction 
(2-3'd) along with three other components. Preparative TLC of the 
mixture gave the main component (excluding starting material) as an 
oil (9 mg) but further TLC showed it to be unstable and the mass 
spectral data was unhelpful.
As expected, hydrogenation deprotection methods (i.e. for removal 
of the benzyloxycarbonyl and benzyl ether groups) on several endothio­
peptides were unsuccessful probably because of catalyst poisoning by 
sulphur.96 A recently developed hydrogenation method,®^ using ammonium
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formate as a hydrogen donor, when applied to (87) gave only unreacted 
starting material.
A considerable amount of time was spent on the deprotection of 
(87) since the deprotected compound would be expected to be more 
a c t i v e . I n  retrospect, the presence of three different protective 
groups on the pentapeptide (87) is probably unwise because at least two 
deprotection steps would be required (although boron tribromide is a 
fairly unselective reagent). The choice of protective groups for (87) 
was dictated largely by the availability of the peptide materials 
Z-Tyr(Bzl)-OH (89) and H-Phe-Leu-OMe (88) at the time. It would be 
synthetically more expedient to use only one, mild deprotection step 
to simultaneously remove all three groups. The tert-butoxycarbonyl and 
tert-buityl®9 protective groups may allow this. In view of the 
diffiGUilties encountered with the deprotection of (87) the synthesis 
of a differently protected monothionated enkephalin was carried out.
2.4.D. Synthesis of BOC-Tyr(BOC)-Glvt-Gly-Phe-Leu-OBu^ (94)
The only difference between this route (Scheme 22) and that 
described in Section 2.4.B. are the two peptide fragments 
BOC-Tyr(BOC)-OH, (95),^°° and H-Phe-Leu-OBu^, (96).^®^
Coupling of the hydrobromide salt (91) with BOC-Tyr(BOC)-OH 
(9 5 ) 1 0 0  uging DPPCl/NMM gave the tripeptide BOC-Tyr(BOC)-Glyt-Gly-OPh 
(93) (62% yield) as a crystalline solid which was considerably more 
soluble in organic solvents than (92) used in Section 2.4.B. and 
consequently easier to purify. The spectral data for (93) was 
completely consistent with that of previous tripeptides containing a 
single thioamide group, with the addition of an extra carbonyl group. 
The unusual tert-butoxycarbonate group carbonyl carbon could be
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distinguished from the other carbonyl carbon signals by its high field 
absorbance (152 ppm) in the ^ n . m . r .  spectrum.
The tripeptide (93) was coupled to H-Phe-Leu-OBu^ (96)^®^ 
following slightly different conditions (refluxing THF, TEA) to those 
used previously for the preparation of (84), (86) and (87) (refluxing 
IPA, TEA) and required a longer reaction time (27 h). After reaction 
some starting tripeptide (92) remained, but column chromatography gave 
the pentapeptide BOC-Tyr(BOC)-Glyt-Gly-Phe-Leu-OBu^ (94) (Scheme 22) 
in reasonable yield (68% corrected). This represents a 28% overall 
yield from Z-Gly-Gly-OPh (21c) and is an improvement on each of the 
previous routes to (87). None of the tripeptide BOC-Tyr-Glyt-Gly-OPh 
(97) arising from displacement of the tyrosyl phenoxy group by the 
dipeptide (96) or the alternative product (98), were isolated suggesting 
that nucleophilic attack occurs predominantly at the ester carbonyl 
(Scheme 23).
The pentapeptide (94) was completely characterized by spectral 
means. Its ^H n.m.r. spectrum (400 MHz) was similar to (87) with the 
exception of three tert-butyl signals at 1*36, 1*45 and 1*54 ppm. The 
characteristic splitting of the para-substituted tyrosine aromatic 
ring^®2 was seen at 7*10 and 7*20 ppm which was at a slightly lower 
field than in (87) due to the electron withdrawing effect of the t-BOC 
carbonate group. The thioamide proton was seen at 9*15 ppm.
The  ̂ n.m.r. spectrum of (94) showed the thiocarbonyl carbon 
at 198*5 ppm with three carbonyl signals at 170-172 ppm (amide), one 
at 167 ppm (ester) and two more at 156 (carbamate) and 151*8 ppm 
(carbonate). The tert-butyl methyl carbons were at 27*7-28*4 ppm 
with the three quaternary t-butyl carbons at 80*3-83*4 ppm. All other 
backbone and side chain carbon signals were consistent with a peptide
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Scheme 22 : Synthesis of BOC-Tvr(BOC)-Glvt-Gly-Phe-Leu-OBu (94)
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a, (95), (70), NMM, -20°C, 0*3 h then (91), RT, 16 h;
b, (96), TEA, THF, A, 27 h.
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of this structure and compared closely with BOC-Tyr(BOC)-Glyt-Gly-OPh 
(93) and with Z-Glyt-Gly-Phe-Leu-OMe (86).
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2.4.E. Deprotection of BOC-Tyr(BOC)-Glvt-Gly-Phe-Leu-OBu^ (94)
In view of the difficulties encountered with the deprotection 
of (87) it was gratifying to find that (94) proved somewhat more 
tractable. However, bearing in mind that the tert-butyl and tert- 
butoxycarbonyl groups normally require much milder acidic cleavage 
methods®®’®^ (than, for instance, the benzyloxycarbonyl group) this 
was not completely surprising.
Indeed deprotection of (94) was achieved using trifluoroacetic 
acid (TEA) in dichloromethane (10%) at room temperature (1*5 h).
This gave a mixture of the trifluoroacetate salt of the completely 
deprotected compound (83) (^H n.m.r., FAB MS) (20%) and a compound with 
one tert-butyl group remaining (31%).
(99)
The latter was assigned the structure (99) based on comparison of its 
n.m.r. spectrum with that of the parent material BOC-Tyr(BOC)-Glyt- 
Gly-Phe-Leu-OBu^ (94) and Z-Tyr(Bzl)-Glyt-Gly-OPh (92). The latter has 
two doublets at 6*85 and 7*15 ppm for the para substituted aromatic 
tyrosyl ring whereas for a compound such as (94) with the electron 
withdrawing t-BOC group these are at a lower field value of 7*10 and 
7*20 ppm. The mono tert-butyl compound (99) has its two doublets at 
6*85 and 7*15 ppm suggesting that the carbonate group has been removed.
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The t-BOC carbamate group is reported as being more acid labile than a 
tert-butyl e s t e r , a n d  this would seem to infer the structure (99) 
for the mono tert-butyl compound.
The n.m.r. spectrum (400 MHz) of the trifluoroacetate salt of 
(83) was fully consistent with its structure and its FAB mass spectrum 
virtually identical in all key features to other reports.
2.5. RECENT RELEVANT WORK
The use of Lawesson’s reagent (25) as a high yielding thionating 
agent‘s® and its application to the synthesis of thioamides^^ has 
led to renewed interest in endothiopeptides. Our own work^^ and the 
independent work of Lawesson’s groupé** has already established that 
simple N-protected dipeptide esters (21) can be readily and selectively 
thionated at the amide link. Even more recently and concurrent with 
this work, reports have been published of other thionated analogues of 
important peptides.
The commercially available sweetener ’Aspartame’ is the 






analogues were p r e p a r e d , u s i n g  (25), from the normal oxygen peptides 









peptide coupling agent, probably via the mixed anhydride species
(102).105
 ̂ "  CĤ CÔ Bzl
0  s _
HNEt.
(102)
The deprotected endothioaspartame (103) was obtained via acid 









The three monothionated analogues of the tripeptide amide, 
H-Pro-Leu-Gly-NH2 (105) (Melanostatin - aneurologically active peptide 
derivative) have also been made.**^^ Two methods for the introduction 
of the thioamide group were used. For H-Pro-Leu-Glyt-NH2 (lObb) 








B O C N H
(107)
oxygen analogue. Subsequent deprotection (HCl/acetone) and coupling 
with BOC-Pro-Leu-OH (108) (using (25) as a coupling agent) gave the 
tripeptide (106a). This was then also deprotected, to give (106b).
A similar direct thionation procedure, followed by deprotection, 
coupling and aminolysis gave the second endothiomelanostatin analogue
(108).
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Scheme 24 : Preparation of HCl.H-Prot-Leu-Gly-NHz (115) 4 3b
BOC' II 0
(109) (110) 
R =  BOC
(111)
c , d
N— ^ ^ S M e
R' II 
S
ls|—\ / L e u -  Gly- NH^ 
R II
(1 1 2) (11 3 )
H -L e u - G ly - N H ,  (115)
H C l . H
N
(114)
a, (25), TEA, RT, 0*1 h then Pip-H, -15°C, 0*25 h, RT, 16 h;
b, (25), PhH, A; c, Mel, THF, RT; d, HgS, MeOH, 0*5 h; e, (115), TEA, 




For the H-Prot-Leu- derivative (115) a completely new procedure 
was used to introduce the thioamide groups indirectly (Scheme 24).
The dithioester (112) was used as a thioacylating agent, Dithioesters 
of this type have been used only briefly for the synthesis of endo­
thiopeptides p r e v i o u s l y . I n  this case the dithioester (112) was 
obtained in four steps from the amino acid derivative, BOC-Pro-OH (109). 
The piperidide (110) was prepared, using (25) to form the intermediate 
mixed anhydride species (102), (R 4̂ CH 2CO 2BZI) which reacted 
exothermally with piperidine. Thionation of (110) proceeded 
exclusively at the amide carbonyl as expected giving the thiopiperidide 
(111). In a ’one-pot’ procedure, the latter (111) was S-methylated 
with excess methyl iodide and then thiolysed with hydrogen sulphide 
giving the dithiomethyl ester ( 1 1 2 ) in reasonably good overall yield 
from (109) (21%). On reaction with the dipeptide ester (115) the 
tripeptide B 0 C-Prot-Leu-Gly-NH2 (113) was obtained (56%) and a 
straightforward deprotection gave the monothio analogue (114).
Originally the latter approach was also going to be used to 
obtain the Leut-Gly derivative (108 ) but the appropriate dithiomethyl 
ester (116) was almost completely unreactive even under more forcing 
c o n d i t i o n s . T h e  large difference in reactivity may be due to the 
greater steric bulk of the leucyl side chain compared to the rigidly
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SMe
B O C N H
(116)
held prolyl molecule. Although the leucyl dithiomethyl ester did not 
give the desired results, this method has obvious application to other 
amino acids.
In fact, during the last few months Lawesson’s group has 
extended this approach to endothioenkephalins.**^ All four suitably 
protected monothioenkephalin derivatives have been made and three of 
thege (Tyrt-Gly, Glyt-Gly and Phet-Leu) have been deprotected to the 
fre^ endothioamino acids. Only the Glyt-Phe compound has not been 
obtained as the deprotected material. This recent work and that 
described in this Thesis are complementary in nature since the 
approaches used are different.
Lawesson appears to favour an indirect method for introduction 




as thioacylating agents, although for the Phet-Leu compound (121) a
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direct method was used. Thus the N-protected dipeptide ester (118) was 
thionated with Lawesson’s reagent (25) giving the endothiopeptide (119) 
(Scheme 25). The latter was deprotected and coupled to the tripeptide 
(122). Final deprotection using hydrogen fluoride and anisole (as a 
cation scavenger)^°^ gave tne totally deprotected monothioenkephalin, 
(121). The latter method was one of the few not tried in the depro­
tection of Z-Tyr(Bzl)-Glyt-Gly-Phe-Leu-OMe (87) although slightly 
different protective groups were used by Lawesson. This route is a 
direct thionation approach (used for the Glyt-Gly compound and 
described in this Thesis) and gives a good overall yield (from 
commercially available BOC-Phe-OH) to the protected pentapeptide (6 8 %). 
It is slightly surprising that it was not used for the other three 
endothioenkephalin analogues.
Instead, for the latter, thioacylation approaches were investi­
gated by Lawesson and co-workers. The thioester method, first used by 
Ried et gj.3^,35,38 Introduction), was applied to the synthesis
of two endothiopeptides Z-Glyt-Gly-Phe-Leu-OBzl (123) and 
Z-Glyt-Phe-Leu-OBzl (124). However, the N-protected thioester used, 
Z-Glyt-OEt (125) gave only complex mixtures when reacted with the 
required free amino peptides, although it could be used successfully 
for the preparation of smaller N-protected dipeptide esters like (55) 
but in only moderate yields (35-38%). In any case this route is 
probably unsatisfactory for chiral amino acids because of the nature 
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a, (25), PhH, A; b, HCl, dioxane, RT, 0-5 h; (122), DCC, -10°C, 1 h, 
RT, 1 0  h; d, HP, PhOCHg, 0°C, 0*5 h.
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Next, the use of N-protected amino acid dithioesters was further 
examined (previously described for Melanostatin**^^) ana found suitable 
for the enkephalin case. The use of N-benzyloxycarbonyl amino acid 
dithioesters, however, gave problems in subsequent deprotection steps 
(this is in accord with our findings on the removal of N-benzyloxycar­
bonyl groups) and therefore N-tert-butoxycarbonyl amino acid 
dithiomethyl esters (130) were used (Scheme 26). The most convenient 
preparation method was the four step route, outlined previously for
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the Melanostatin endothio analogues, shown in Scheme 26.
All the steps in the sequence proceed in good yield (56-91%) 
and the intermediate methiodides (129) were isolated in this case.
The dithiomethyl esters (130) were reactive thioacylating agents and 
on coupling with the required free amino peptide esters by either step­
wise or fragment procedures gave the suitably protected (BOC amino, 
benzyl ether and benzyl ester) monothioenkephalins (Tyrt-Gly, Glyt-Gly 
and Glyt-Phe). The final step in all cases used hydrogen fluoride/ 
anisole (106) as the deprotection agent. However, for the Glyt-Phe 
derivative (Z-Tyr(Bzl)-Gly-Glyt-Phe-Leu-OBzl) the deprotected compound 
could not be isolated and the method failed in this instance.
The overall yields, from commercially available starting 
materials, for the fully protected pentapeptides in the Tyrt-Gly and 
Glyt-Phe cases are quite respectable (30% and 38%) but the latter 
compound has not been deprotected. For the Glyt-Gly example the overall 
yield is not significantly different (29%) to the work described herein 
for BOC-Tyr(BOC)-Glyt-Gly-Phe-Leu-OBu^ (94) (26%). The best yield is 
for the Phet-Leu example (120) where the direct nature of the route is
reflected in the higher value (6 8 %).
The fact that Lawesson's group used the indirect method for
thioamide incorporation and thus avoided all attempts at carboxyl 
terminus deprotection until the final stage may reflect the 
difficulties encountered in this regard (also described in Section 
2.2. and by Lajoie et The Phenyl ester method circumvents
this problem.
In connection with the work described in the following section 
(2 .6 .) we have since found that the indirect method of introduction
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of the thioamide group used by Lawesson**^ is unsatisfactory for 
N-protected amino acids with ’bulky’ side chains (e.g. valine). 
Thionation of the piperidide of BOC-Valine, (132a) with (25) proceeded 
only slowly and gave a poor yield of product (132b) (30%). Furthermore, 
the attempted méthylation of (132b) following Lawesson’s work does not
B O C N H  
X
( 1 3 2 )  a : X =  0  
b ; X =  S
proceed even when more vigorous refluxing conditions are applied 
(although stronger methylating agents have not been tried). It may be 
that the steric bulk of the valyl side chain prevents the C-N bond 




The use of a ’’modified Lawesson’s reagent” (27a) has been 
reported recently^^ and, in fact, a fully protected Glyt-Gly enkephalin 
(131b) has been prepared in one step from the pentapeptide (131a)
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rapidly (3*5 h) and in good yield (75%).
(131) BOC-Tyr(BOC)-Gly-Gly-Phe-Leu-OMe a X=Q
^ b X=S
However, other methods to introduce the thioamide group at more 
sterically ’crowded’ amide links will probably be required. Indeed 
the phosphetane disulphide (27a) (Belleau’s reagent” ) gave lower 
yields with more hindered amino acid peptides (for example (134) and 
(135)), and also required higher temperatures (40, 50°C) and longer
Ph






reaction times (24, 48 h ) , than for glycine containing peptide 
derivatives (0-23°C, 0*1-3*5 h).
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2.6. APPROACHES TOWARDS THE SYNTHESIS OF ENDOTHIOAZIRIDINE PEPTIDES
The progress of the work aimed at the synthesis of the cyclic 
peptide Ascidiacylamide^^ is discussed below. The retro-synthetic 
scheme (Scheme 9) outlined in the Introduction focused attention on 
the endothioaziridine peptide unit (37) and our initial efforts were 
directed at this target.
I T
0  II
( 39)  X =  0  
( 3 7 )  X =  S
It seemed likely that the direct thionation of a suitably pro­
tected derivative of type (39) (probably prepared by peptide coupling 
of a valine derivative with a suitable aziridine) would give the 
desired endothioaziridine structure (37) although the stability of 
these systems was not known.
The 2-aziridine carboxylic acid derivative (139) was prepared in a 
three step sequence from serine methyl ester hydrochloride salt (136) 
(Scheme 27) following the route used by Japanese workers and described 
in detail^^’®® for the 3-methyl-2-aziridine carboxylic acid derivative 
(140). This sequence applied to serine methyl ester (136) gave 
N-triphenylmethyl-2 -aziridine carboxylic acid methyl ester (139) in a 
high degree of purity and in excellent overall yield. Although the 
preparation of aziridine (139) is described in the literature^^»^® 
its spectroscopic details are absent. Peptides containing the ’A z y ’ 
























( 1 4 0 )
a , P h 3 CCI, TEA, 0°C, 2 h, RT, 18 h; b, Ts Cl, py, -10°C, 2*5 d; 
c, TEA, THE, A, 2*5 d.
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(139) showed the aziridinyl protons clearly as doublets of doublets at 
1*4 (3H, trans), 1*9 (aH) and 2*3 ppm (gH, cis). The coupling constants 
were used to aid the assignments. The geminal coupling between the 3
Tr-N:
/H g  cis• 11 H g  trans
: " i H
(139)
a
C O z M e
protons was small (1*5 owing to the effect of the ring environ­
ment. The coupling between the 3H (cis) and aH was less (2*5 Hz) 
than that between the other 3H (trans) and the aH (6 Hz).
The aziridine is stable in its protected form and could be stored 
indefinitely at room temperature without adverse effects. No untoward 
difficulties were encountered with its handling provided precautions 
were taken to avoid exposure to agents likely to open the ring (for 
example, HCl).




BOC N H "  Y  (142)
0  II 0
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Next, the aziridine (139) was deprotected and coupled to 
BOC-Val-OH (141) to furnish the novel dipeptide BOC-Val-Azy-OMe (142) 
This was accomplished most conveniently, without isolation of the 
deprotected aziridine (143), using a solution of TFA (33%) in
OMe
II0
( 1 4 3 )
MeOH/CHCla at room temperature and subsequent reaction with the mixed 
anhydride (144). The latter is easily formed from BOC-Val-OH (141)
0 P ( 0 ) P h g
BOC N H ^  Y  
0
( 1 4 4 )
and DPPCl (70) at low temperatures (-20°C). This two step sequence 
gave a moderate overall yield (39%) of the dipeptide (142). The latter 
clearly shows the aziridine protons still present in the ^H n.m.r. 
spectrum at 2*7 (3 protons) and at 3*25 ppm (aH) although they have been 
shifted downfield compared to (139) by the electron w i t h d r a w i n g  ’acyl' 
group. The ^H n.m.r. spectrum also shows the valyl methine protons 
at 2*2 (CH Meg) and 4*2 ppm (NH CH) with the latter coupled (J = 9 Hz) 
to the carbamate NH proton.
The ^^C n.m.r. spectrum of this dipeptide has three carbonyl
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carbon signals at 155*7, 168*6 and 182*8 ppm consistent with the 
carbamate, ester and amide groups of an aziridine dipeptide. The 
double bond character of the C-N bond is reduced, compared to ’normal’ 
peptides, as evidenced by the downfield shift of the amide carbon 
(which usually resonates at ~170 ppm in more conventional peptides). 
Other signals observed are as expected for a valyl amino acid residue 
with the aziridine ring carbons at 30*6 (CH2 N) and 34*4 ppm (CH N).
The lower than expected yield in this reaction can be partly 
explained by the isolation of another dipeptide product (9%) from the 
reaction. This was identified as a valyl-alanine derivative (145) 
arising from ring opening of the aziridine by a nucleophilic species 
(X). The identity of the nucleophile was thought to be a chloride ion
N H
BOCNH OMe
( 1 4 5 )
which is only present in the reaction mixture as N-methylmorpholine 
hydrochloride. This may, however, be sufficient to cause ring opening. 
Evidence for N-tert-butoxycarbonyl-3-chloroalanine was provided by n.m.r 
and ^^C n.m.r. spectra which were similar to the spectra for 
B O C - V a l - S e r - O M e . ^ T h e  mass spectrum of (145) showed several ion 
pairs of two mass units difference in the ratio of 3:1 (isotopic ratio 
of ^^C:^^C) although the molecular ion did not show this feature and 
this cannot be explained.
With the desired aziridine peptide (142) to hand we investigated
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its thionation with a view to forming the endothioaziridine (146). It 
was suspected, from a literature comparison with thioacyl 
aziridines,^^*^^ that the postulated product (146) would rearrange 
under the reaction conditions to the 2-thiazoline (147) .
BOC NH OMe ( 145)
BOCNH"^ ^  T  "OMe (147)
However, treatment of the aziridine peptide (142) with 
l.awesson’s reagent (25) at elevated temperatures (80°C) was unsuccess­
ful. Although one reaction gave, by TLC analysis, an unstable product 
that was different from the starting dipeptide (142), this could not be 
repeated. This product had a n.m.r. spectrum that was consistent 
with the endothioaziridine dipeptide (146) and, as expected, this was 
similar to starting material (142).
Milder thionation conditions were employed using the alternative 
phosphetane disulphide ( 2 7 a ) . T h e  attempted thionation of 
BOC-Val-Azy-OMe (142) at room temperature with "Belleau's reagent"
(27a) did not yield the suspected endothioaziridine (146), obtained 
above, but gave, after column chromatography, a more polar product. 
Although this was originally thought to be a single component, closer 
examination revealed it to be a mixture which could not be separated. The
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n.m.r, spectrum showed the presence of both aromatic protons 
(7-8 ppm) and those attributable to the BOC-Val- segment of the 
aziridine dipeptide (142). The aziridine ring protons were not seen. 
In an attempt at further resolution a high field (400 MHz) spectrum 
was obtained but this showed the sample to be even more complex than 
at first thought and was not helpful.
Lawesson's reagent (25) is known to form insertion products with 
small membered rings. For example, 3-lactones (148) give unusual 
heterocycles (149).^^° More relevantly, perhaps, the a-amino ketone 
(150) gave the 2,3-dihydro-l,3,2-thiaza-phosphole ( 1 5 1 ) . The 
corresponding 1,3,2-thiazaphospholidine-2-oxides (152)^^^ and 
2-sulphide-4-carboxylic acids (153)^^^ have been prepared by other 
routes, the latter from an amino acid derivative and a suitable 
phosphorus reagent.
a







Ph"  "  -  Ph
(2 5 )
P h N ^
Ph
NHPh
( 1 5 0 )  (151)
The structure of the product from the reaction of BOC-Val-Azy-OMe 
(142) with Belleau's reagent (27a) is (very) tentatively proposed as 






(1 5 2 ) (153)
(154). The latter might be formed by attack of the phosphetane 
sulphide species (155)^^^ on the aziridine ring of the dipeptide (142)
BOCNH
A r
( 1 5 4 )
and subsequent ring opening. In support of this structure the n.m.r
P h O - ^ P ^
(155)
spectrum contains the t-butyl, valyl, methyl ester and aromatic protons 
in the correct integral ratios. The mixture of products may be 
explained by a mixture of diastereoisomers at the chiral centres of 
(154) (including phosphorus) and this may also go some way to 
explaining the complexity of the n.m.r. spectrum. However, the 
product may be unstable, which would complicate the correct assign-
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ment of chemical shift values. Thiazaphospholidine oxides (152) are 
reported to be susceptible to hydrolysis.^^^
The mass spectrum (Cl) of the product also supports the 
structure (154). The highest significant ion was observed at m/e 464 
which is 1 0 0  mass units lower than the molecular ion of structure 
(154). However, loss of the tert-butoxycarbonyl group from (154) 
would explain this result. Another fragment ion is seen at m/e 448 
which may correspond to a further loss of NH 2- from the 464 fragment. 
The base peak at m/e 105 and other significant ions (331, 278) are, 
however, unexplained.
In view of these results, we turned to the use of phosphorus 
pentasulphide (P2S 5 ) as a thionation agent. A recent application‘s** 
used ultrasound to improve the homogeneity of the reaction medium and 
this excluded the need for high temperatures. Under these conditions**** 
the starting dipeptide was consumed within a short time (<3*5 h). 
Howe\^er, after an aqueous work-up, and column chromatography to obtain 
the non-polar materials, a poor yield (~35%) of a colourless oil was 
obtained that did not chromatograph cleanly. This suggested a 
mixture and/or unstable product(s).
The ^H n.m.r. (60 MHz) of the oil showed the t-butyl, valyl and 
methyl ester protons (in the correct integral ratio) but the rest of 
the spectrum was not fully resolved. A mass spectrum (Cl) of the 
product(s) showed an ion at m/e 317 which is the molecular mass (+1) 
of the 2-thiazoline (147). Although other fragment ions (261, 217), 
consistent with the thiazoline (147) were seen, the base peak at m/e 
279 could not be explained by this product. The base peak may have 
arisen from a higher m/e value fragment or molecular ion (m/e 335) by 
the loss of 2-butene (C^Hg) and this seems to suggest a mixture of
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products.
The use of an indirect route for the incorporation of the 
thioamide functionality was next explored since a clean product could 
not be obtained from the PgS^ method. Lawesson’s groupez*43 ^ave 
used dithioesters as thioacylating agents and this was investigated. 
The required valyl dithioester derivative (156) should be available 













The novel piperidide (132a) was prepared in a high yielding step 
(95%) from BOC-Val-OH (141) using DPPCl (70) and NMM to form the 
mixed anhydride species (144) in situ and subsequent reaction with 
piperidine. This peptide coupling agent gives consistently clean, 
efficient reactions when used with nitrogen nucleophiles. The 
piperidide (132a) had fully consistent n.m.r., IR and mass spectra.
Thionation of the latter product (132a) with Lawesson’s reagent 
(25) was quite sluggish, compared to other thionation reactions, and 
the thiopiperidide (132b) was only formed in poor yield (23%). Some 
of the starting piperidide (132a) was also recovered (17%). The 
product was characterized by its n.m.r. and n.m.r. spectra.
The latter showed the appearance of a thiocarbonyl carbon signal 
(202*7 ppm) when compared to the piperidide (132a). The amide carbon 
of the latter (170*2 ppm) was not present in the sulphur analogue 
(132b).
The attempted méthylation of the thiopiperidide using methyl 
iodide (excess) in THF following an identical method to that of 
Lawesson et gave unreacted starting material even under more
vigorous conditions (refluxing THF). Since it was suspected that the 
methiodide (133) would not be chromatographically stable, the reaction 
mixture was evaporated and the ^H n.m.r. spectrum of the residual oil 
obtained. This, however, was identical with that of the starting 
thiopiperidide (132b).
The reason for the lack of reactivity of the thiopiperidide 
(132b) towards méthylation is not clear. The steric bulk of the valyl 
side chain may create an undesirably crowded environment in the 
methiodide (133). The enforced planarity of the C=N double bond may 
•be sufficiently unfavourable to prevent product formation. However,
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the planarity of the C-N bond would also be present in the thioamide 
(132b) to a considerable degree and thus this reason does not seem 
completely justified.
Several approaches for the synthesis of the endothioaziridine 
(146) from a suitable peptide derivative using methodology described 
earlier in this work have been explored. Although it is suspected 
that the endothioaziridine (146) is not particularly stable, other 
products have not been proved. The aziridine ring of the dipeptide 
(142) does not seem sufficiently stable to allow thionation with 
phosphetane disulphides ((25) and (27a)) and this is clearly a limita­
tion to their use. We have shown that the most synthetically useful 
indirect method**^ for incorporation of the thioamide group appears 
to be also limited, by sterically encumbered amino acids. The phos­
phorus pentasulphide method is the most promising but lack of time has 
precluded a further investigation of the products obtained.
2,7. CONCLUSION
This work has described suitable procedures for incorporation of 
the thioamide functionality into small biologically important peptides 
( the enkephalins) which will allow other thioamide analogues of 
peptide molecules to be synthesised and investigated. During the 
course of the work various peptide coupling and deprotection methods 
have been investigated for their suitability in these new systems.
The choice of protective groups for these analogues is important 
when larger (tri, tetra and penta) peptides are required. Two pro­
tected enkephalins with the Gly-Gly amide bond replaced by a thioamide 
have been prepared by different routes. The deprotection of one of the 
endothioenkephalins has been achieved giving the free amino
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endothiopeptide acid (83).
The use of endothiopeptides as synthetic intermediates for 
heterocyclic peptide synthesis has been investigated. This has been 
successful as a preliminary exploration and points the way to other 
efficient applications.
E X P E R I M E N T A L
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SOLVENTS AND REAGENTS
Solvents were distilled and dried, prior to use, by standard 
m e t h o d s , w h e n  required. Reactions involving moisture sensitive 
materials were carried out under an inert atmosphere of dry nitrogen. 
All evaporations were carried out in vacuo below 60°C.
Most amino acid and peptide derivatives used as starting 
materials were commercially available. Other derivatives were pre­
pared by literature methods as cited. The latter were homogeneous 
by TLC and n.m.r. The author thanks ICI Pharmaceuticals Division 
(Macclesfield) for gifts of other selected starting materials.
CHROMATOGRAPHY
TLC was carried out using commercially available pre-coated 
silica gel 60 F 2 5 4 , or ’reverse phase’ silica, plates. Visualiza­
tions in both cases were achieved by ultra-violet fluorescence at 
254 nm and/or the following spray reagents^





Medium pressure column chromatography was carried out using 
silica gel (Merck 7747) or modified 'reverse phase’ silica.
SPECTROSCOPY
Nuclear magnetic resonance (n.m.r.) spectra were recorded at 
100 MHz (^H) or 22*5 MHz (^^C) unless stated otherwise. All spectra
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were run in deuteriochloroform (CDCI3 ) or deuterium oxide (D2O) with 
tetramethylsilane (TMS) or p-dioxane as internal standards unless 
specified otherwise. Chemical shifts (6 ) are expressed downfield from TMS 
in all cases with multiplicities denoted by s (singlet), d (doublet), 
t (triplet), q (quartet), p (pentet), dd (doublet of doublets) or m 
(multiplet). Assignments are expressed as the atom (or group) concerned 
followed by, either, its adjacent atom (or group) or, the amino acid 
residue (of the peptide) in which it occurs. For the n.m.r.,
spectral multiplicities are those observed in the OFR (off field
4-
resonance) spectra. Aromatic carbons were assigned according to the
following labelling of the ring atoms:
Tyrosyl 0 CH, —
Phenylalanyl
Phenyl ester
Where this information was obtained by an INEPT (insensitive 
nuclei enhancement by polarization transfer) spectrum the 
data is presented as if an OFR spectrum had been run.
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Infra-red (IR) spectra were recorded as Nujol mulls with the 
absorption frequencies (v) expressed in cm” ^.
Ultra-violet (UV) spectra were recorded as ethanolic solutions
unless stated otherwise. Maximum absorptions (A ) are expressed in^ max ^
nm with the molar absorptivity (e) as 10”  ̂ m^ mol~^.
Mass spectra (MS) were recorded using electron impact (El) at 
70 eV unless otherwise stated.
The author thanks the Science and Engineering Research Council 
(SERC) for use of the high field (400 MHz) n.m.r. facility at the 
University of Warwick.
OTHER TECHNIQUES
All melting points are uncorrected.
Elemental analyses were carried out by Butterworth Laboratories 
(Teddington) and the accurate mass measurements obtained by the Physical 
and Chemical Measurements Unit (Harwell).
INSTRUMENTATION
^H n.m.r. J.E.O.L. PS 100 (100 MHz)
Varian EM360 (60 MHz)
Perkin-Elmer R24B (60 MHz)
^^C n.m.r. J.E.O.L. FX 90 Q (22*5 MHz)
I.R. Perkin-Elmer 197 and 1310
U.V. Perkin-Elmer 402 and Lambda 3
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Thionation of N-protected dipeptide ester substrates (21)
The preparation of Z-Glyt-Gly-OPh (55c) and Z-Alat-Ala-OMe (55e) 
are given as examples of the thionation reaction. The experimental 
details for other N-protected endothiodipeptide esters are shown in 
Table 5. Unless otherwise stated, all thionations were carried out 
in dry toluene at 80-90°C (0*5-2 h) using Lawesson’s reagent (25)
(0*55 molar equivalent).**® Medium pressure column chromatography of 
the reaction mixture after evaporation gave the products (55) and (23) 
as white solids or colourless gums.
N-Benzyloxycarbonyl-thioglycyl-glycine phenyl ester (55c)
A suspension of Z-Gly-Gly-OPh (21c) (2*57 g , 7*5 mmol)^®*^^® and 
Lawesson’s reagent (25) (1*6 g, 4 mmol) in dry toluene (50 ml) was 
heated (1 h) at 80-90°C. The resulting solution was cooled to room 
temperature and the solvent evaporated giving an oily semi-solid 
residue. The crude material was subjected to medium pressure column 
chromatography (5% EtOAc/DCM) and the fractions containing the desired 
product (R^ 0*3) combined and evaporated. This gave the title compound 
as a slightly off-white solid (1*90 g, 70%). 
mp 92*5-94*0°C
^H n.m.r. 6 4*20 (2H, d, 6 Hz, CHg Glyt^), 4*55 (2H, d, 5 Hz, CHg Gly^),
5*10 i2H, s, CHzO), 5*80 (IH, hr t, NH Glyt^), 7-7*40 (lOH, s, m, Ar),
8*70 (IH, hr s, NH Gly=).
n.m.r. 6 47*0 (t, CH^ GlyZ), 52*0 (t, CH^ Glyt^), 67*5 (t, CHgO),
212*2 (d, C OPh), 126*4 (C , OPh), 128*0 (C , P h C H J ,  128*3 (C ,p o p  0
PhCH^), 128*6 (C^, PhCHg), 129*6 (C , OPh), 136*1 (s, C^, PhCH^),
150*2 (s, C^, OPh), 156*8 (s, C=0, carbamate), 167*2 (s, C=0, ester), 
201*0 (s, C=S).
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I.R. 3220, 3300 (NH), 1765 (C=0, ester), 1695 (C=0, carbamate).
U.V. X^^^(CHCl 3 ). 265 ( e = l *6 x 10**).
Mass (m/e), 264 (M-PhOH, 0-7), 156 (264-PhCH20H, 2*5), 94 (PhOH, 100).
Acc. mass: C 1 2H 1 2 H 2O 3S (M-PhOH) requires 264*0566, found 264*0557.
N-Benzyloxycarbonyl-thioalanyl-alanine methyl ester (55e)
A suspension of Z-Ala-Ala-OMe (55c) (250 mg, 0*8 mmol)^^® and 
Lawesson’s reagent (25) (190 mg, 0;47 mmol) in dry toluene (20 ml) was 
heated at 85-95°C (2 h). The resulting solution was cooled to room 
temperature and the solvent evaporated. The oily residue was subjected 
to medium pressure column chromatography (10% EtOAc/DCM). The fractions 
containing the desired product (R^ 0*4) were combined and evaporated to 
give the title compound as a colourless, viscous oil (260 mg, 1 0 0 %) 
that retained solvent traces tenaciously.
^H n.m.r. (400 MHz), 6 1*45 and 1*46 (3H, d, 7 Hz, CH 3 Alat^, Ala^),
3*75 (3H, s, OCH 3 ), 4*60 (IH, m, CH Ala^), 5*05 (IH, p, 7 Hz, CH Alat^),
5*10 (2H, q, 13 Hz, OCH2 ), 5*70 (IH, hr d, NH Alat^), 7*35 (5H, m,
aromatic), 8*5 (IH, br s, NH Ala^).
n.m.r. 6 16*7 and 22*3 (q, CH 3 A l a t \  Ala=), 52*4 (q, OCH 3 ), 53*4 
(d, CH Ala=), 56*3 (d, CH Alat^), 67*1 (t, PhCH2 0 ), 127*8-128*5 (3C, 
aromatic), 136*2 (C^, aromatic), 155*9 (s, C=0, carbamate), 172*2 (s, 
C=0, ester), 205*5 (s, C=S).
I.R. (Liq. film), 3300 (NH), 1700-1750 (broad, C=0, ester,
carbamate).
U.V. A (CHCI3 ), 270 (E = 1-09 X 10**)  max ^
Hass (m/e) 324 (M"̂ , 6 ), 216 (M-PhCHjOH, 22), 184 (216-MeOH, 10),
108 (PhCHzOH, 43), 91 (C7H 7+, 100).
Acc. mass: CisH?nN^OuS requires 324*1139, found 324*1151.
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N-Benzyloxycarbonyl-thioglycyl-glvcine methyl ester (55a) 
mp Table 5
n.m.r. 6 3*75 (3H, s, OCH 3 ), 4-25 (2H, d, 7 Hz, CHz Gly=), 4*4 (2H,
d, 6 Hz, CH 2 Glyt^), 5*1 (2H, s, PhCH_2 0 ), 5*9 (IH, br t, 6 Hz, NH Glyt^),
7*3 (5H, s, aromatic), 8 * 6  (IH, br t, NH Gly^).
^^C n.m.r. ô 46*7 (t, CH 2 Gly^), 51*9 (q, OCH 3 ), 52*5 (t, CH 2 Glyt^),
67*4 (t, CH 2O), 128*0-128*6 (3C, aromatic), 136*1 (C^, aromatic),
156*8 (s, C=0, carbamate), 168*8 (s, C=0, ester), 200*7 (s, C=S). 
I ^ v ^ a x »  3300, 3400 (NH), 1750 (C=0, ester), 1710 (C=0, carbamate).
U.V. X^^^(CHCl3 ), 266 (E f= 1-27 x 1 0 **).
Mass (m/e), 296 (M'"', 28), 188 (M-PhCH2 0 H, 3), 156 (188-MeOH, 2),
91 (C7H 7+, 100).
Acc. mass; CigHipN,0&S requires 296*0827. found 296*0833. 
N-Benzyloxycarbonyl-thioglycyl-glycine 4-methoxybenzyl ester (55b) 
mp Table 5
^H n.m.r. 6 3*75 (3H, s, O C H 3), 4*2 (2H, d, 6 Hz, C H 2 Glyt^), 4*4 (2H, 
d, 5 Hz, C H 2 Gly:), 5*1 (4H, s, PhCHjO, ArCHgO), 6*9 (2H, d, 9 Hz,
(MeO)Pji), 7*0-7*4 (8 H, aromatic (7H), NH Glyt^), 9*6 (IH, br t,
NH Gly=). (CDCl3 /DMS0 -d 6 )
^^C n.m.r. 6 46*7 (t, C H 2 Gly=), 51*6 (t, C H 2 Glyt^), 55*1 (q, OCH 3),
6 6 * 6  and 66*7 (t, ArÇH 2 0 ), 113*9 (d, C_, (MeO)Ph-), 128*1-130*0
(aromatic), 136*6 (s, C ^ P h C H 2), 156*7 (s, C^, (MeO)Ph-), 159*7 (s,
C=0, carbamate), 168*1 (s, C=0, ester), 201*3 (s, C=S). (CDCl3 /DMS0 -d 6 )
I.R. , 3350 (NH), 1740 (C=0, ester), 1700 (C=0, carbamate).
U.V. X , 264 (E = 1*23 X 10^).  max
Mass (m/e), 402 (M+, 1-4 ), 294 (M-PhCHzOH, 2-5), 121 ( M e O - ^ ^ - C H 2+, 
100), 91 (C7 H 7 +. 55).
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N-tert-Butoxycarbonyl-thioglycyl-glveine benzyl ester (55d) 
mp Table 5
n.m.r. 6 1*45 (9H, s, C H 3 ), 4-2 (2H, d, 5 Hz, CH 2 Glyt^), 4*45 (2H, 
d, 5 Hz, C H 2 Gly=), 5-2 (2H, s, PhÇH 2 0 ), 5-6 (IH, br t, NH Glyt^),
7*35 (5H, s, aromatic), 8 * 8  (IH, br s, NH Gly^).
^®C n.m.r. 6 28-3 (q, C H 3 ), 46*5 (t, CH 2 Gly=), 52*1 (t, C H 2 Glyt^), 
67*5 (t, OCH 2 ), 80*8 (s, (CHs)^ Ç-), 128*3-128*6 (aromatic), 135*1 (s, 
C^ aromatic), 156*3 (s, C=0, carbamate), 168*4 (s, C=0, ester), 201*0 
(s, C=S).
Vmax» 3350 (NH), 1730 (C=0, ester), 1690 (C=0, carbamate.
U.V. X^^^(CHCl3), 266 (E = 1*28 X 10**).
Mass (m/e), 338 (M\ 7), 282 (M-C^He, 17), 265 (M-C4H 9O, 5), 91 (C7H 7+, 
100), 57 (C4 H 9 , 42).
Acc. mass: C 1 6H 2 2 N 2O 4S requires 338*1295, found 338*1302.
N-Benzyloxycarbonyl-thioglycyl-phenylalanine methyl ester (23) 47
mp Table 5
^H n.m.r. 6 3*20 (2H, dd, 6 Hz, CH 2 Phe^), 3*6 (3H, s, OCH 3 ), 4*1 (2H, 
d, 6 Hz, CH 2 Glyti), 5*0 (2H, s, OCH 2 ), 5*55 (IH, m, CHPhe^), 6*0 (IH, 
t, 6 Hz, NH Glyt^), 7*0-7*4 (10 H, s, m, aromatic), 9*6 (IH, br d,
NH Phe=).
^^C n.m.r. 6 36*3 (t, CHg Phe^), 51*8 (t, CH 2 Glyt^), 52*3 (q, OCH 3 ), 
58*3 (d, CH Phe=), 67*1 (t, OCH 2 ), 127*1-129*1 (aromatic C), 135*3 and 
136*0 (C^, aromatic), 156*6 (s, C=0, carbamate), 170*8 (s, C=0, ester), 
199*9 (s, C=S).
Vmax* 3340 (NH), 1700-40 (C=0, ester, carbamate).
W »  265 (e = 1.34 x lOT).
Mass (m/e), 386 (M+, 1 1 ), 353 (M-MeOHg, 3*5), 251 (M-Z, 5),
+ +
162 (PhCH2=CHC02Me, 37), 91 (C7H 7 , 100).
Acc. mass: C^nHo^NpO^S, calc. 386*1295, found 386*1300.
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N-Benzyloxycarbonvl-thiophenvlalanyl-glycyl methyl ester (55f) 
mp Table 5
n.m.r. 6 3-1 (2H, dd, 2 Hz, 7 Hz, CH 2 Phet^), 3*7 (3H, s, OCH 3 ),
4*2 (2H, d, 5 Hz, CH 2 Gly^), 4*9 (IH, m, CH Phet^), 5*0 (2H, s, 
PhCH2 0 ), 5*8 (IH, d, 9 Hz, NH Phet^), 7*2 (5H, s, aromatic), 7*3 (5H, 
s, aromatic), 8*35 (IH, br s, NH Gly^).
^^C n.m.r. ô 42*2 (t, CH 2 Phet^), 46*8 (t, C H 2 Gly=), 52*3 (q, OCH 3 ), 
62*6 (d, CH Pheti), 67*1 (t, PhÇH2 0 ), 127*0-129*3 (aromatic), 136*3 
and 136*5 (C^, aromatic), 155*9 (s, C=0 , carbamate), 168*5 (s, C=0, 
ester), 204*1 (s, C=S).
l.R. 3325 (NH), 1750 (C=0, ester), 1695 (C=0, carbamate).
U.V. ^max^CHCls), 269 (e = 1*23 x lOf).
Mass (m/e), 386 (M'"', 0-7), 278 (M-PhCHjOH, 17), 219 ( 278-CO, MeO, 12), 
91 (C7H 7+, 1 0 0 ).
Acc. mass: C 2 0 H 2 2 N 2O 4 S requires 386*1295, found 386*1301. 
N-Benzyloxycarbonyl-thioisoleucyl-glycine methyl ester (55g) 
mp Table 5
^H n.m.r. ô 0*9 and 0-95 (3H, s, CH 3 lletJ), l*0-2*0 (3H, br m, 
CHqCHzCHfCH,) lleti), 3*7 (3H, s, OCH 3 ), 4*2-4*55 (3H, m, CHg GlyZ, CH
lleti) 5*1 (2H, s, PhCHzO), 5*95 (IH, d, 9 Hz, NH llet^), 7*3 (5H, s,
aromatic), 9*2 (IH, br s, NH Gly^).
^®C n.m.r. ô 11*0 and 15*4 (q, CH 3 lleti), 24*8 (t, CH^ lleti), 39*8 
(d, ÇH(CH 3 )CH2CH 3 ), 46*6 (t, CHg GlyZ), 52*3 (q, OCH 3 ), 65*3 (d, CH, 
(i-Bu) lleti), 67*0 (t, PhCHgO), 127*6-128*4 (aromatic), 136*3 (s, C , 
aromatic), 156*5 (s, C=0, carbamate), 168*6 (s, C=0, ester), 205*8 (s, 
C-S).
l.R. (Liq. film), 3300 (NH), 1700-1750 (C=0, ester, carbamate).
U.V. A (CHCI3 ), 269 (e = 1*13 x 1 0 “).  max ^
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Mass (m/e), 352 (M"̂ , 3), 296 (M-C»H$, 2), 220 (6 ),
188 (296-PhCHzOH, 20), 176(23), 91 (C7H 7+, 100).
Acc. mass; C 1 7 H 2 4 N 2O 4S requires 352*1451, found 352*1459.
ThioRlycyl-glycine methyl ester hydrobromide salt (61)
A mixture of Z-Glyt-Gly-OMe (55a) (640 mg, 2*2 mmol) and HBr/AcOH 
(45% w/v, 10 ml) was stirred at room temperature (1 h) in a flask 
protected from moisture ingress (CaCl2 ). Dry ether (50 ml) was added 
and the white precipitate filtered off and washed with a small amount 
of ether (10 ml). This afforded the title compound as a white powder 
(500 mg, 95%). 
mp 171*0-173*0°C (decomp.)
n.m.r. 6 3*70 (3H, s, OCH 3 ), 3*90 (2H, br s, CH 2 Glyt^), 4*40 (2H,
d, 4 Hz, C H 2 Gly=), 8*25 (3H, br s, N H 3+), 11*0 (IH, br s, NH) (DMSO-dJ.
n.m.r. 6 47*2 and 47*8 (t, GHz Glyt^ Gly=), 53*6 (q, OCH 3 ), 169*5 
(s, C=0, ester), 198*0 (s, C=S), (DMSO-de).
Vmax> 3000 (NH2 , broad), 1745 (C=0, ester).
U.V. (H2O), 262 (e = 1*06 x 10“ ).
Mass (m/e), 162 (M-HBr, 65), 145 (I6 2 -NH 3 , 3). 133 (I6 2 -CH 2NH, 21),
+
30 (CH2NH 2 , 1 0 0 ).
Acc. mass: C 5H 1 0N 2O 2S (M-HBr) requires 162*0461, found 162*0475.
N-Benzyloxycarbony1 -alanyl-thioglycy1 -glycine methyl ester (63)
To a suspension of the hydrobromide (61) (242 mg, 1 mmol) and
Z-Ala-OH (62) (223 mg, 1 mmol) in DCM (10 ml) at 0-5°C was added a
solution of TEA (101 mg, 1 mmol) in DCM (5 ml) and the reaction stirred 
(0*1 h ) . A solution of DCC (206 mg, 1 mmol)^® in DCM (10 ml) was added 
slowly dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred overnight. The white precipitate (DCU) was
106.
filtered off and the filtrate evaporated and subjected to medium 
pressure column chromatography (5% EtOH/CHClg). The fractions 
containing the desired product (R^ 0*35) were combined and evaporated 
to afford the title compound as a white, crystalline solid (290 mg,
79%).
m £  108-109°C
n.m.r. 6 1-40 (3H, d, 7 Hz, C H 3 Ala^), 3-70 (3H, s, OCH 3 ), 4*3 (5H, 
m, CHz G l y t S  Gly®, CH A l a M ,  5-05 (2H, s, PhCH,0), 5*90 (IH, d, 6 Hz,
NH Ala^), 7*3 (5H, s, aromatic ), 7*55 (IH, br t, NH, Glyt^), 9*00 (IH,
(br t), NH, Gly®).
^^C n.m.r. 6 18-2 (q, C H 3 Ala"), 46-9 (t, CHz Gly®), 50*1 (t, CHg Glyt=), 
51-2 (d, CH Alai), 52-5 (q, CH 3O), 67-2 (t, PhCHzO), 128-0-128-6 
(aromatic, 3C), 136-2 (C^, aromatic), 156-5 (s, C=0, carbamate), 169*0 
(s, C=0, ester), 173*6 (s, C=0, amide), 200*3 (s, C=S). 
l.R. 3300 (NH), 1750 (C=0, ester), 1700 (C=0, carbamate), 1670
(C=0, amide).
U.V. (CHCI3 ), 267 (e = 1*15 x 1 0 “).
Mass (m/e), 3 6 7 (M+, 32), 259 (M-PhCHzOH, 14), 161 (Glyt-Gly-OMe, 12),
91 (C7 H 7+, 100).
Acc. mass: CiAHpiNsOsS requires 367*1197, found 367*1215.
Thioglycyl-glycine benzyl ester trifluoroacetate salt (64)
A solution of BOC-Glyt-Gly-OBzl (55b) (169 mg, 0*5 mmol) in 
aqueous TEA (90% v/v, 10 ml) was stirred at room temperature (0*5 h).
The solvent was evaporated and toluene (2 x 20 ml) used (azeotrope 
formation) to aid the removal. This gave a colourless, viscous oil 
which crystallized on standing to afford the title compound as a 
white solid (140 mg, 94%). 
mp 129-131°C (decomp.)
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*H n.m.r. 6 3-95 (3H, s, CHz Glyt*), 4-50 (2H, s, CHz Gly'), 5-20 (2H,
+
s, PhCHzO), 7*40 (5H, s, aromatic), 8*9 (3H, v br s, N H 3 ). (DMSO-de).
13C n.m.r. 6 45*8 (t, CH 2 Glyt^), 46-5 (t, C H 2 Gly^), 66*1 (t, C H 2Ph),
127'9-128'3 (3C, aromatic), 135*6 (C^, aromatic), 167*5 (s, C=0, ester), 
196*8 (s, C=S). (DMSO-de).
I.R. V , 3200 (NH), 1760 (0=0, ester), 1690 (0=0, TFA).
U.V. X (H2O), 262 (e = 1*07 x 10^).  max ^
Mass (m/e), 238 (M"̂ ,TFA 17), 221 (238-NHs, 2), 209 (NHzCH loss, 20), 
147 (2 3 8-C7H7+, 6), 130 (238-PhCHzOH, 6).
Acc. mass: C i 1H 1 4 N 2O 2 S (M-TFA) requires 238*0773, found 238*0769.
Thioisoleucyl-glycine hydrobromide salt (65)
A solution of Z-llet-Gly-OMe (55g) (200 mg, 0.57 mmol) in
HBr/AcOH (48% w/v, 5 ml), protected from moisture ingress (CaCl2 ), 
was stirred at room temperature (1*5 h ) . Ether (50 ml) was added and 
the whole evaporated. The slightly orange oily residue was evaporated 
from DCM ( 5 x 5  ml) giving an orange solid. After washing with ether 
(10 ml) the title compound was obtained as a pale orange powder (75 mg, 
83%).
mp 175-179°C (decomp.)
^H n.m.r. 6 0*90 (3H, t, 7 Hz, CH^CHgCH), 0*95 (3H, d, 6 Hz, CH^CH),
1 *0-2*1 (3H, m, CH 3CH 2ÇH), 4*05 (IH, d, 7 Hz, CH l l e t ^ ,  4*45 (2H, s,
CHz GlyZ).
^®C n.m.r. 6 0 * 8  and 14*9 (q, CH 3 llet^), 24*8 (t, CHz llet^), 39*1 (d, 
ÇHCH 2CH 3 ), 47*6 (t, CHz GlyZ), 63*5 (d, ÇH C(S)), 172*1 (s, C=0, acid), 
200*8 (s, C=S).
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Thioglycyl-glycine hydrobromide salt (6 6 )
A solution of Z-Glyt-Gly-OMe (55a) (190 mg, 0*64 mmol) in 
HBr/AcOH (48% w/v, 10 ml) was heated at 55°C ( 6 h). The reaction 
mixture was cooled to room temperature and ether (50 ml) added. The 
precipitated white solid was filtered and washed with a small amount 
of ether (<10 ml). This gave the title compound (140 mg, 95%) as a 
cream powder. 
mp 91-94°C
^H n.m.r. 6 3*9 (2H, s, GHz), 4*1 (2H, s, CHz), 4*75 (s, HDO).
I.R. V , 2800 (OH, broad), 1615 (C=0, acid).  max
W  (HzO)' 259
Mass (m/e), 148 (M'*'-HBr, 0-5), 130 (M+-HBr-HzO, 7), 114 (IBO-NHz, 47), 
80, 82 (HBr, 50 each), 30 (100).
Acc. mass: C^HeNzOS (M-HBr-H2 0 ) requires 130*0200, found 130*0201.
Thioglycyl-phenylalanine methyl ester hydrobromide salt (6 8 )
A solution of Z-Glyt-Phe-OMe (23) (2*07 g , 5*4 mmol)“  ̂ in AcOH 
(glacial, 2 ml) was treated with HBr/AcOH (48% w/v, 8 ml) and the 
solution stirred at room temperature (0*5 h). Ether (50 ml) was added 
and the precipitate filtered off and washed with ether ( 2 x 2 0  ml). 
This afforded the title compound as a white powder (1*41 g, 79%), 
clearly homogeneous by TLC (5% MeOH/CHClg, R^ 0*5, UV, Ninhydrin 
yellow), which was used immediately.
^H n.m.r. (60 MHz), 6 3*2 (2H, dd, 2Hz, 7Hz, CH^ Phe?), 3*65 (3H, s, 
OCH 3 ). 3*9 (2H, s, CHz Glyti), 4*6 (HDO), 5*2 (IH, t, 7Hz, CH Phe^), 
7*2 (5H, s, aromatic).
Mass (m/e), 252 (M-HBr, 10), 235 (252-NHs, 48), 203 (235-MeOH, 41),
162 (2 5 2 -C 7H 6+, 33), 91 (C7H 7+, 100).
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N-Benzyloxycarbonvl-glycyl-thioglycyl-phenylalanine methyl ester (71)
To a suspension of Z-Gly-OH (69) (847 mg, 4 mmol) in DCM (80 ml) 
at -20°C was added DPPCl (70) (1000 mg, 4*2 mmol) and NMM (0*45 ml,
4*1 mmol) and the mixture stirred (0*25 h). The hydrobromide (6 8 ) 
(1*349 g, 4*1 mmol) and NMM (0*55 ml, 5 mmol) were added and the 
reaction allowed to reach room temperature and stirred overnight. The 
reaction mixture was evaporated and the crude residue treated with 
EtOAc (50 ml). The resultant suspension was washed with aqueous 
sodium bicarbonate solution (5%, 2 x 25 ml). The organic phase was 
separated and washed further with aqueous citric acid (5%, 2 x 25 ml) 
and water (2 x 25 ml). The organic layer was dried (MgSO^), filtered 
and evaporated.^
The orange oil thus obtained was subjected to medium pressure 
column chromatography (25% EtOAc/DCM). The fractions containing the 
desired product were combined and evaporated to give the title compound 
as a white solid (1*2 g, 67%). 
m£ 54*5-56°C
n.m.r. 6 3*25 (2H, dd, 5*5 Hz, 5*5 Hz, CHg Phe®), 3*65 (3H, s, 
OCH3 ), 3*8 (2H, d, 6Hz, CHz G l y M ,  4*2 (2H, m, CHz Glyt^), 5*10 (2H, s, 
PhCHzO), 5*35 (IH, m, CH Phe®), 5*9 (IH, t, 5Hz, NH Gly^), 7*l-7*4 
(lOH, m, s, aromatic), 7*5 (IH, t, NH Glyt^), 8*95 (IH, d, 7 Hz, NH 
Phe®).
^^C n.m.r. 6 36*6 (t, CHz Phe®), 44*6 (t, CHz Gly^), 49*9 (t, CHz 
Glyt=), 52*4 (q, OCH3 ), 58*9 (d, CH Phe®), 67*3 (t, PhCHzO), 127*2- 
136*2 (aromatic), 156*7 (s, C=0, carbamate), 170*0 (s, C=0, ester), 
171*0 (s, C=0, amide), 199*5 (s, C=S).
^Unless stated otherwise, all peptide coupling reactions were 
worked up in this standard fashion.
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I.R. 3350 (NH), 1740 (C=0, ester), 1680 (C=0, carbamate), 1660
(0 =0 , amide).
U.V. X , 265 (e = 1-22 x 10“).   max
Mass (m/e), 443 (M'"', 3), 411 (M-MeOH, 1-5), 335 (M-PhCHjOH, 11), 
303 (335-MeOH, 6-5), 91 (C7H 7+, 100).
Elemental Analysis, Found: C, 59*46; H, 5*86; N, 9*60; S, 7*14. 
Calc, for C 2 2 H 2 5 N 3O 5S : C, 59*6; H, 5*64; N, 9*48; S, 7*22.
N-Benzyloxycarbonyl-thioglycy1-glycine (13a) 3 5
To a solution of Z-Glyt-Gly-OMe (55a) (140 mg, 0*47 mmol) in 
acetone ( 8 ml) was added a solution of sodium hydroxide (0*25 M, 2 ml) 
and the reaction stirred at room temperature (18 h). A further 
aliquot of sodium hydroxide solution (3 drops) was added and the 
coloured (red) solution stirred (1 h). The reaction mixture was 
partially evaporated, to remove acetone, and water (23 ml) added to 
the liquid residue. The aqueous solution was extracted with ether 
(25 ml, 10 ml) and then acidified (2 M, HCl) to pH 1. The aqueous 
solution was again extracted, with EtOAc (2 x 25 ml), and the organic 
phase dried (MgSOu), filtered and evaporated affording a slightly 
coloured (orange) solid (72 mg, 55%) consisting of predominantly the 
title compound.
n.m.r.t Ô, 4*2 (2H, d, 6 Hz, CHz Gly^), 4*3 (2H, d, 5 Hz, CHz Glyt^), 
5*10 (2H, s, CHzO), 7*10 ( IH, br s, NH Gly^), 7*35 (5H, s, aromatic),
9*4 (IH, br t, NH Gly^). (20% DMS0 -d 6 /CDCl3 ).
I_i^ Vmax> 2900 (OH), 1730 (C=0, carbamate), 1700 (C=0, acid).
Mass (m/e), 282 (M"̂ , 2), 264 (M-HzO, 1-25), 91 (C7H 7 ‘̂ , 100).
^Other (minor) signals seen but unassigned
111.
N-Benzyloxycarbonyl-glycyl-thioglycyl-phenylalanine (77)
To a solution of Z-Gly-Glyt-Phe-OMe (71) (150 mg, 0*34 mmol) 
in THF (9 ml) was added a solution of sodium hydroxide (0*39 M,
0*9 ml) and the mixture stirred at room temperature (18 h). After 
this time some of the ester (71) still remained. Additional sodium 
hydroxide solution (0*5 ml, total 1*6 equiv.) was added and the mixture 
stirred for a further period (5*5 h). The solution was partially 
evaporated to remove THF and the residual liquid partitioned between 
water (10 ml) and ether (10 ml). The aqueous layer was washed with a 
further ether aliquot (5 ml) and then acidified (pH 1-2) with hydro­
chloric acid (2 M ) . Extraction with EtOAc (3 x 10 ml), drying of the 
organic phase (MgSO^), filtration and evaporation gave a slightly 
coloured (yellow) oil (130 mg) which comprised predominantly the title 
compound by TLC (10% MeOH/CHClg, 1% AcOH; 0*4) and ^H n.m.r. (60 MHz).
n.m.r.T (60 MHz) 6 3-2 (2H, m, CHz Phe^), 3-8 and 4-2 (2H, ra, CHz G l y S
Glyt^), 5-0 (IH, s, CHzO), 5-3 (IH, m, CH Phe^) 7-1 and 7-2 (5H, s,
aromatic), 7*8 (IH, br t, NH Phe®), 9*0 (IH, br d, NH Glyt^) (CDCla/de-
acetone).
Attempted preparation of Glycyl-thioglycyl-phenylalanine methyl ester 
hydrobromide salt (78)
To a solution of Z-Gly-Glyt-Phe-OMe (71) (40 mg, 0*09 mmol) in
acetic acid (1 ml) was added a solution of HBr/AcOH (48% w/v, 0*5 ml) 
and the reaction stirred at room temperature (0*5 h ) . Ether was
^This sample was not homogeneous as evidenced by an additional 
broad singlet at 6 * 9  ppm, the low integral value for the 
singlet at 5*0 ppm and TLC. However, purification by medium 
pressure column chromatography (4% MeOH/CHClg, 1% AcOH) was 
feasible giving a moderate yield of the title compound (60%) 
as an off-white foam.
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added and the whole extracted with water (25 ml). The aqueous layer 
was evaporated to afford a coloured (orange) semi-crystalline solid.
TLC analysis of this material and n.m.r. (60 MHz) identified it 
probably as the doubly deprotected tripeptide, glycyl-thioglycyl- 
phenylalanine hydrobromide salt (78) although a rigorous characteriza­
tion was not carried out.
^H n.m.r. (60 MHz) Ô 3*0 (2H, m, CHz Phe®), 3*7 and 3*8 (4H, 2s, CHz 
Glyi, Glyt^), 4*2 (IH, m, CH Phe^), 7*1 (5H, s, aromatic), (all other 
protons exchanged with solvent).
Attempted preparation of N-Benzyloxycarbonyl-thioglycyl-glycine
4-nitrophenyl ester (81)
A suspension of Z-Gly-Gly-ONp (80) (250 mg, 0*65 mmol)^^° and 
Lawesson’s reagent (25) (144 mg, 0*36 mmol) in dry toluene (10 ml)
was heated at 80°C (0*25 h). The resultant yellow solution was 
cooled to room temperature. TLC analysis of the mixture (50% EtOAC/DCM) 
showed that no starting material remained and a possible product (R^
0*7, UV, I2 orange) had formed. This material was not stable to 
medium pressure column chromatography with silica although some 
fractions were combined and evaporated to give a small amount of 
para-nitrophenol (82) (identified by 60 MHz  ̂H n.m.r.).^^^
N-Benzyloxycarbony1 -thioglycyl-glycy1 -glycine methyl ester (84)
A mixture of Z-Glyt-Gly-OPh (55c) (171 mg, 0*5 mmol), glycine 
methyl ester hydrochloride (85) (63 mg, 0*5 mmol) and TEA (51 mg,
0*5 mmol) in IPA (25 ml) was refluxed (8*5 h). The resulting 
solution was cooled to room temperature, the solvent evaporated and 
the crude residue subjected to medium pressure column chromatography 
(30% EtOAc/DCM). The fractions containing the desired product (R^
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0*15) were combined and evaporated. This gave the title compound as 
a white solid (83 mg, 47%).
2 2  130'5-132'5°C
n.m.r. 6 3-70 (3H, s, OCH 3 ), 3-90 (2H, d, 6 Hz, CHz Gly®), 4-20 
(2H, d, 6 Hz, CHz Glyt^), 4-30 (2H, d, 5 Hz, CHz Gly=), 5*10 (2H, s, 
PhCHzO), 7*3 (6 H, s, aromatic , NH Glyt^), 8*25 (IH, br t, NH Gly®), 
9-60 (IH, br t, NH Gly=). (CDCI3 /DMSO-de).
^^C n.m.r. 6 40*9 (t, CHz Gly=), 48*1 (t, CHz Gly^), 52*0 (q, t, CHz 
GlyS, OCH 3 ), 66*7 (t, PhCHzO), 127*9-129*0 (3C, aromatic), 136*5 
(s, C^, aromatic), 156*7 (s, C=0, carbamate), 167*8 (s, C=0, ester), 
169*9 (s, C=0 , amide), 2 0 0 * 2  (s, C=S). (CDCI3 /DMSO-de).
I.R. 3300 (NH), 1745 (C=0, ester), 1700 (C=0, carbamate), 1665
(C=0, amide).
U.V. X (CHCI3 ), 267 (e = 1*1 x 10*).  max ^
Mass (m/e), 3 5 3 (M+, 5), 319 (M-MeOH, 3), 245 (M-PhCHzOH, 29), 108 
(PhCHzOH, 50), 91 (C7H 7+, 100).
Acc. mass; C 1 5 H 1 9 N 3O 5 S requires 353*1041, found 353*1044.
N-Benzyloxycarbonyl-thioglycyl-glycyl-phenylalanyl-leucine methyl ester
(86)
A solution of Z-Glyt-Gly-OPh (55c) (700 mg, 1*96 mmol), 
phenylalanyl-leucine methyl ester hydrochloride salt (8 8 ) (808 mg,
2*46 mmol) and TEA (278 mg, 2*75 mmol) in IPA (50 ml) was heated to 
reflux (2*5 h). The reaction mixture was cooled to room temperature 
and the solvent evaporated to give a dark residue. The crude material 
was washed in the usual way and subjected to medium pressure column 
chromatography (30% EtOAC/DCM). The fractions containing the desired 
product (R^ 0 *2 ) were combined and evaporated to afford the title 
compound.(420 mg, 43% (corrected)) as a white solid after trituration
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with a small amount of petroleum ether (40-60).
2 2 . 110-111-0°C
n.m.r. (400 MHz) 6 0-87 and 0-88 (3H, d, 6 Hz, C H 3 Leu*), 1-45-1-63 
(3H, m, CH 2CH(CH 3 )2 ), 2-95 (IH, dd, 7-5 Hz, 14 Hz, CHz Phe^), 3-07 (IH, 
dd, 6 Hz, 14 Hz, CHz Phe^), 3-70 (3H, s, OCH 3 ), 4-15-4-42 (4H, m, CHz 
G l y t \  Gly^), 4-55 (IH, m, CH-CHzCH(CH3 )z), 4-90 (IH, m, CH Phe®),
5-11 (2H, q, 12 Hz, PhCHzO), 6-10 (IH, br t, NH Glyt^), 7-1-7-35 (12H, 
complex, Ar, 2NH P he^, Leu*), 9*05 (IH, br s, NH Gly^).
^^C n.m.r. 6 21-3 and 22-7 (q, C H 3 Leu*), 24-2 (d, CH(CH 3 )z Leu*),
40-3 (t, CHz Leu*, CHz Phe^), 47-6 (t, CHz, Gly^), 50-4 and 51-3 (d,
CH Leu*, CH Phe^), 51-7 (t, CHz Glyt^), 53-7 (q, OCH 3 ), 65-8 (t, 
PhCHzO), 126-2-129*1 (aromatic ), 136*8 and 137-6 (C^, aromatic ),
156*0 (s, C=0, carbamate), 166-7 (s, C=0, ester), 171-0 and 172-6 (s, 
C=0, amide), 200-1 (s, C=S) (DMSO-dp).
I ^ V m a x »  3320 (NH), 1740 (C=0, ester), 1640 (C=0, amide).
U.V. X 264 (e = 8*79 x 10®).  max
Mass (m/e) (FAB +), 557 (M+1, 11), 525 (M-MeOH, 3). 293 (Hz-Phe-Leu-
+
OMe+, 51), 146 (Hz-Leu-OMe"^, 90), 1 2 0  (PhCHzCHNHs, 100).
Thioglycyl-glycyl-phenylalany1 -leucine methyl ester (90)
To a solution of Z-G1yt-Gly-Phe-Leu-OMe (8 6 ) (387 mg, 0*7 mmol) 
in AcOH (1*5 ml) protected from moisture ingress (CaClz) was added a 
solution of HBr/AcOH (48% w/v, 1 ml) and the reaction mixture stirred 
at room temperature (0*5 h). The mixture was diluted with ether 
(10 ml) and extracted into water (30 ml). The aqueous phase comprised 
two main components by TLC (5% MeOH/CHCl3 ) at 0-6 (weakly UV active, 
Ninhydrin purple) and R^ 0*3 (UV, Ninhydrin yellow). This mixture was 
basified (xs TEA) and extracted into EtOAc (5 x 10 ml). The organic 
phase was dried (MgSO^), filtered and evaporated. The crude residue
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was subjected to medium pressure column chromatography (5% MeOH/CHCla).
The fractions containing mainly the higher product were 
combined and evaporated to give a coloured (yellow) oil which solidified 
in air and was identified from this and subsequent experiments as 
H-Phe-Leu-OMe (8 8 ) (48 mg, 23%).
n.m.r. (60 MHz)"^ 6 0*9 (6 H, d, 4 Hz, C H 3 Leu^), 1*5 (3H, m, 
CH 2CH(CH3 )2 ), 3-0 (2H, m, CHz Phe^), 3-6 (3H, s, OCH 3 ),4-4-5 (2H, m,
CH P h e \  CH Leu^), 7-0 (5H, s, aromatic), 7-4 (IH, br d, NH Phe^).
Mass (m/e), 260 (M'^'-MeOH, 12), 204 (2 6 O-C4H 8 , 14), 120 (HzN=CHCHzPh,
23), 91 (C7H 7+, 62).
The fractions containing the lower R^ material were treated in 
the same manner giving a colourless oil (140 mg, 47%) identified, 
tentatively at this stage, as the title compound (90).
n.m.r. (60 MHz)"^ ô 0-9 (6 H, d, 4Hz, CH3 Leu*), 1-5 (3H, br m, 
CHzCH(CH3 ) 2 Leu*), 3-0 (2H, d, 6 Hz, CHz Phe®), 3-55 (5H, s, OCH3 ,
MeOH), 3-8-4-8 (7H, m, CHz G l y t \  G l y \  CH Phe®, CH Leu*, NH), 6-9 
(6 H, s, aromatic, N H ) , 7*4 (IH, d, 8 Hz, NH).
Mass (m/e) (Cl), 391 (M+-Z-MeOH, 3), 301 (3 9 I-C7H 6+, 7), 261 
(H-Phe-Leu+, 95).
N-Benzyloxycarbony1-0-benzyl-tyrosy1 -thioglycyl-glycf"Pkenylalanyl-
leucine methyl ester (87), [4+1] route
To a solution of Z-Tyr(Bzl)-OH (89) (118 mg, 0-3 mmol) in DCM 
(10 ml) at -20°C was added DPPCl (70) (69 mg, 0-3 mmol) and NMM (39 mg, 
0*39 mmol). The reaction mixture was stirred (0*3 h) and a solution of 
the tetrapeptide (90) (122 mg, 0*29 mmol) in DCM (5 ml) added. The
^These samples gave broader resonances in their n.m.r. 
spectra than was usually observed.
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reaction was allowed to attain room temperature and stirred overnight. 
The solvent was evaporated and the crude residue partitioned between 
EtOAc (25 ml) and aqueous NaHCOa (5% w/v, 15 ml). The organic phase 
was washed with further NaHCOg (15 ml), followed by aq.
HCl (1-4 M, 2 X 15 ml). After drying (MgSO^), filtration and evapora­
tion the crude material was subjected to medium pressure column 
chromatography (2*5% MeOH/CHClg). Fractions containing the desired 
product (R^ 0*35) were combined and evaporated to afford the title 
compound as a white solid (130 mg, 56%) after trituration with a small 
amount of ether. 
mp 162*5-164°C (decomp.)
^H n.m.r. (400 MHz) 6 0-91 (3H, d, 7 Hz), 0*94 (3H, d, 7 Hz),
1-44-1-66 (3H, m), 2-68 (IH, dd, 10 Hz, 14 Hz), 2-75 (IH, dd, 11 Hz,
14 Hz), 3-04 (2H, dd, 3 Hz, 14 Hz), 3-60 (3H, s), 4-05 (2H, dd, 5-5 Hz, 
18 Hz), 4*15 (2H, dd, almost coincident, 5*5 Hz, 18 Hz), 4-21 (IH, m), 
4-27 (IH, m), 4-59 (IH, t of d), 4-91 (2H, q, 16 Hz, 2 Hz), 5-05 (2H, 
s), 6 - 8 8  (2H, d, 8  Hz), 7-18 (2H, d, 8  Hz), 7*2-7*5 (15H, m ) , 7*55 
(IH, d, 8 Hz), 8-35 (IH, d, 10 Hz), 8-38 (IH, d, 8 Hz), 8-54 (IH, t,
5 Hz), 9*67 (IH, br t). (Assignments see Figure 5).
^ m a x ’ 3325 (NH), 1740 (C=0, ester), 1700 (C=0, carbamate), 1655 
(C=0, amide).
U.V. A , 267 (e = 1*05 x 10*).  max
Mass (m/e) (FAB +), 810 (M""" + 1, 8 ), 676 (M-Z, 12), 120 (HzN+^CHCHzPh, 
100).
Elemental Analysis, Found: C, 65*08; H, 6*49; N, 8*56; S, 4*18.
Calc, for C^^HsiNsOgS : C, 65-24; H, 6-35; N, 8-65; S, 3-95.
Thioglycyl-glycine phenyl ester hydrobromide salt (91)
A solution of HBr/AcOH (48% w/v, 6 ml) was added to
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Z-Glyt-Gly-OPh (55c) (535 mg, 1*5 mmol) in a flask fitted with a 
drying tube (CaCl2 ). The resultant solution was stirred at room 
temperature (0*5 h ) , Ether (25 ml) was added and the precipitate 
filtered off and washed with a small amount of ether (<10 ml). After 
drying in air the title compound was obtained as a cream powder 
(439 mg, 96%) clearly homogeneous by TLC (5% MeOH/CHCla) (R^ 0*25, 
Ninhydrin yellow). 
mp >200°C (decomp.)
n.m.r. 6 4-60  (4H, m, GHz), 7-0-7-4 (5H, m, OPh), 8-5 (3H, br s,
+
N H 3 ), 11-10 (IH, br t, NH). (CDCla/DMSO-de).
I.R. 3000 (NH2 , broad), 1760 (0=0, ester).
U.V. A (H2O), 262 (e = 1-16 x 10*).  max
N-Benzyloxycarbonvl-O-benzyl-tyrosyl-thioglycyl-glycine phenyl ester
(92 )
To a solution of Z-Tyr(Bzl)-OH (89) (582 mg, 1-4 mmol) in 
DOM (20 ml) at -20°C was added DPPCl (70) (343 mg, 1-45 mmol) and NMM 
(145 mg, 1-45 mmol) and the mixture stirred (0-25 h ) . The hydro­
bromide (91) (439 mg, 1-3 mmol) and additional NMM (145 mg, 1-45 mmol) 
were added. The reaction was allowed to reach room temperature and 
then stirred overnight. After evaporation of solvent the crude 
residue was washed in the usual way. Drying of the organic phase 
(MgSO^), filtration and evaporation gave an oily residue. Trituration 
with petroleum ether (60-80) afforded the title compound as an 
essentially pure cream solid (815 mg, 92%). Additional purification 
was achieved by medium pressure column chromatography (15% EtOAc/DCM) 
(R^ 0*25) to give a white solid. 
mp 141-142°C (decomp.)
n.m.r. Ô 3-0 (2H, m, CHg Tyr%), 4-3 (3H, br m, CH 2 G l y \  CH Tyr^),
118.
4*5 (2H, br m, GHz Glyt^), 5*0 (4H, s, C H 2O), Ô-8-7-4 (20H, s, m, Ar,
NH Tyri), 8*4 (IH, br t, NH Glyt^), 9-7 (IH, br t, NH Gly^) (CDCla/DMSO-de) 
^ n . m . r .  6 45*1, 47*9 and 49-8 (t, GHz, Glyt^, Gly^, Tyr^), 56*8 (d,
GH Tyri), 66-3 and 69-7 (t, GHzO), 114-6 (CL, Tyr^), 121-4 (CL, OPh), 
125-9-130-3 (aromatic), 136-5 and 137-0 (s, G^, Z, Bzl), 150-4 and 
156-5 (s, G^, Tyr^, OPh), 157-3 (s, G=0, carbamate), 166-5 (s, G=0, 
ester), 172-1 (s, G=0 , amide), 201-4 (s, G=S). (GDGla/DMSO-de).
I.R. , 3300 (NH), 1760 (G=0, ester), 1690 (G=0, carbamate), 1670 
(G=0, amide).
U.V. A , 264 (e = 8-15 x 10=).  max
Mass (m/e),(FAB +), 612 (M+H).
Elemental Analysis, Found: G, 66-75; H, 5-40; N, 6-87; S, 5-23.
Gale, for G 3 4 H 3 3N 3O 6S: G, 66-78; H, 5-51; N, 6-70; S, 5-15.
N-Benzyloxycarbonyl-O-benzyl-tyrosyl-thioglycyl-glycyl-phenylalanyl- 
leucine methyl ester (87), [3+21 route
A mixture of Z-Tyr(Bzl)-Glyt-Gly-OPh (92) (800 mg, 1-3 mmol), 
phenylalany1-leucine methyl ester hydrochloride salt (8 8 ) (500 mg,
1-5 mmol) and TEA (328 mg, 3-25 mmol) in IPA (60 ml) was refluxed (2 h).
The reaction was cooled to room temperature and evaporated before 
washing in the usual way. The organic phase, after drying (MgSOi*), 
filtration and evaporation was subjected to medium pressure column 
chromatography (50% EtOAc/DGM). Fractions containing the title compound 
(R^ 0*25) were combined and evaporated giving a slightly coloured solid. 
Trituration with ether ( 1 0  ml) afforded the title compound as a white 
solid (300 mg, 29%) identical to that prepared by the [4+1] route 
(TLG, ^H n.m.r. (60 MHz), MS).
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Reaction of Z-Tyr(Bzl)-Glvt-Gly-Phe-Leu-OMe (87) with Trifluoroacetic 
acid (TFA)*o
A solution of the protected pentapeptide (87) (40 mg, 0*05 mmol) 
in TFA (0*5 ml) was kept at room temperature in an n.m.r. sample tube 
(26 h). n.m.r. (60 MHz) after this time was not conclusive of any 
change. However, TLC (5% MeOH/CHCla, NHg) evidence showed that no 
further starting material remained. The solvent was evaporated and the 
coloured (orange) oil partitioned between aqueous NaHCOs solution 
(5%, 10 ml) and ether (10 ml). The aqueous phase was washed with a 
further ether aliquot (10 ml). The organic phase contained a baseline 
component (some streaking) plus a material which was identical by 
TLC (R^ 0*7, Ninhydrin purple) to the dipeptide H-Phe-Leu-OMe (8 8 ).
This experiment was not pursued further.
Reaction of Z-Tyr(Bzl)-Glyt-Gly-Phe-Leu-OMe (87) with TFA/TFMSA 93
A solution of the protected pentapeptide (87) (72 mg, 0*09 mmol) 
in TFA (3 ml) was treated with anisole (0*1 ml, 0*9 mmol) and then 
TFMSA (250 mg, 1*7 mmol) and the resultant coloured (red) solution 
stirred at room temperature (0*75 h). Water (2 ml) was added and the 
mixture partially evaporated. The residue was partitioned between 
water (20 ml) and EtOAc (20 ml). The organic phase was washed with a 
further water aliquot (10 ml) and then dried (MgSO^), filtered and 
evaporated. The aqueous phase was also evaporated. The ^H n.m.r. 
spectrum showed no organic materials present. The residue from the 
organic layer appeared to be more than one component by TLC. The
n.m.r. spectrum showed the absence of the characteristic thioamide NH 
proton at 8-9 ppm. In view of these unpromising results no further 
action was taken.
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Reaction of Z-Tyr(Bzl)-Glyt-Glv-Phe-Leu-OMe (87) with Boron tribromide**
A cooled (-10°C) solution of the pentapeptide (87) (56 mg,
0*07 mmol) in a mixture of DCM (1 ml) and dimethylacetamide (1*5 ml) 
was treated with a solution of boron tribromide in DCM (1*0 M, 0*35 ml, 
0*35 mmol). The reaction mixture was warmed to room temperature (1 h) 
and stirred (3 h). ’Wet’ methanol (3 ml) was added and the solution 
evaporated. After further evaporations from methanol (2 x 3 ml) an oily 
residue was obtained which consisted predominantly of starting material 
by TLC (5% MeOH/CHClg, NH 3 ).
Reaction of Z-Tyr(Bzl)-Glyt-Gly-Phe-Leu-OMe (87) with Boron tribromide 
and TFA*:
A suspension of the pentapeptide (87) (52 mg, 0*06 mmol) in dry 
DCM (10 ml) was treated with the minimum amount of TFA (~0*1 ml) 
necessary to dissolve the substrate and the solution cooled (-10°C).
A solution of boron tribromide in DCM (1*0 M, 0*5 ml, 0*5 mmol) was 
added and the mixture stirred at -10°C (1 h) and then at room 
temperature (1*5 h ) . Water (5 ml) was added slowly and the solution 
evaporated from methanol ( 3 x 5  ml) to remove any boron compounds 
present.
The coloured (orange) residue was taken into water (25 ml) once 
more and washed with EtOAc (25 ml). After evaporation the aqueous 
residue (four components by reverse phase TLC, 50:50, MeOH:water) 
was treated with an aqueous solution of TEA (0*7%, 1 ml) and water 
(20 ml). However, extraction with EtOAc (25 ml, 10 ml, 5 ml) was 
unsuccessful, so the basic water layer was re-evaporated to a small 
volume (1 ml) and the four components separated by descending prepara­
tive paper chromatography (Whatman 3M; 70:20:10, 1-Butanol:water:AcOH).
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After extraction with ethanol (50 ml) the major component 
was obtained as a gum (5 mg).
Mass (m/e) (Cl), No signals above 500 mass, 261 (H-Phe-Leu-OH-HzO, 100).
Alkaline hydrolysis of Z-Tyr(Bzl)-Glyt-Glv-Phe-Leu-OMe (87)
A solution of the pentapeptide (87) (50 mg, 0*062 mmol) in THF 
(2*5 ml) was treated with aqueous sodium hydroxide (0*135 M, 0*5 ml, 
0*675 mmol) and the mixture stirred (4 d). After this time substantial 
amounts of starting material (87) still remained. The solvent was 
partially evaporated to remove THF and partitioned between water (20 ml) 
and EtOAc (25 ml). The organic phase was separated, dried (MgSO%), 
filtered and evaporated. The crude residue, which consisted of 
starting material (87) plus three other components by TLC (10% 
MeOH/CHCla, 1% AcOH), was dissolved in a small amount of EtOAc (2-3 ml) 
and applied to a preparative TLC plate. Elution of the plate (10% 
MeOH/CHClg, 1% AcOH), removal of the four component sections and 
extraction with THF gave recovered pentapeptide (87) (25 mg, 0*031 
mmol) and the other main product (R^ 0*25) as a coloured oil (9 mg).
Tne other two components were not pursued.
Mass (m/e) (Cl), 444 (7*6), 437 (7*8), 369 (6 *8 ), 305 (6*4),
285 (7*4), 219 (100).
Attempted hydrogenation*^ of Z-Tyr(Bzl)-Glyt-Gly-Phe-Leu-OMe (87)
To a suspension of the pentapeptide (87) (110 mg, 0*14 mmol) in 
methanol (4 ml) was added AcOH (5 ml). The resulting solution was 
treated with ammonium formate (34 mg, 0*54 mmol) and 10% Pd on 
charcoal (50 mg) and stirred at room temperature (1 h). TLC (5% 
EtOAc/CHCla, NH3 ) showed that little or no reaction had occurred. 
Recovery of starting material was achieved by filtration through a
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pad of Celite followed by evaporation of the filtrate. The residue 
was taken into EtOAC (60 ml) and washed with saturated brine 
(2 X 20 ml). The organic phase was dried (MgSOu), filtered and 
evaporated. The residue (100 mg) was identical with starting material 
(87) (TLC).
N.O-BisTtert-butoxycarbonyll - tyrosyl-thioglycyl-glycine phenyl ester
(93)
To a solution of BOC-Tyr(BOC)-OH (95) (1*25 g, 3*28 mmol)^°° 
in DCM (20 ml) at -20°C was added DPPCl (70) (816 mg, 3*45 mmol) and 
NMM (0*4 ml, 3*7 mmol) and the mixture stirred (0*3 h). The hydro­
bromide (91) (1*0 g, 3 mmol) and additional NMM (0*6 ml, 5*5 mmol) 
were added. The reaction was allowed to reach room temperature and 
then stirred overnight (~18 h). After evaporation of solvent the crude 
residue was washed in the usual way. Drying of the organic phase 
(MgSO%), filtration and evaporation gave an oily residue which after 
medium pressure column chromatography (15% EtOAc/DCM, 0*3) afforded 
the title compound as a white crystalline solid (1 * 2  g, 62%) which 
became slightly yellow on standing in air. 
m £  76*5-78*5°C
n.m.r. (60 MHz) 6 1-35 (9H, s, ([^3 ) 3 C-), 1-50 (9H, s, ([^3 ) 3 C-), 
3-0 (2H, br m, CH 2 Tyr^), 4-3 (3H, m, d, 5 Hz, CH T y r \  CHz Gly^), 4-5 
(2H, d, 5 Hz, GHz Glyt=), 5-3 (IH, d, 7 Hz, NH Tyr^), 7-0-7-4 
(9H, m, aromatic), 7*4 (IH, br m, NH Glyt^), 9*0 (IH, br t, NH Gly^).
^^C n.m.r. 6 27*7 and 28*3 (q, ( ^ 3 ) 3 C), 37-2 (t, CHz Tyr%), 46*9 (t, 
CHz Glyt=), 50-1 (t, CHz Gly^), 56-3 (d, CH Tyr^), 80*6 and 83*5 (s, 
(CH3 )g C-), 121*4 (s, C g , OPh Tyr^), 126*2-134*0 (4C, C^, C^, aromatic), 
150*1 and 150*4 (s, C^, OPh Tyr^), 151*9 (s, C=0, carbonate), 156*0 (s, 
C=0, carbamate), 166*9 (s, C=0, ester), 172*4 (s, C=0, amide).
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200-8 (s, C=S).
I.R. 3200-3400 (NH), 1750 (C=0, ester, carbonate), 1660 (C=0,
amide, carbamate).
U.V. X , 264 (e = 1-08 x 10*).  max
Mass (m/e),(FAB +), 588 (M+1, 14), 532 9), 516 (M-C4HSO+, 4)
432 (532-BOC, 9).
Elemental Analysis, Found, C, 59*49; H, 6*42; N, 7*06; S, 5*53.
Cale, for C 2 9 H 3 7 N 3O 8S: C, 59*28; H, 6*30; N, 7*16; S, 5*45.
N,0-Bis[tert-butoxycarbonyll-tyrosyl-thioglycyl-glycyl-phenylalanyl- 
leucine tert-butyl ester (94)
A solution of BOC-Tyr(BOC)-Glyt-Gly-OPh (93) (270 rag, 0*46 mmol), 
H-Phe-Leu-OBu^ (96) (157 mg, 0*47 mmol)^°^ and TEA (0*25 ml, ^4 eq.) 
in THF was refluxed (27 h). The solution was cooled to room tempera­
ture and evaporated. The crude oily residue (orange) was subjected to 
medium pressure column chromatography (25-50% EtOAc/DCM) to give 
recovered starting material (93) (identical by TLC, 60 MHz ^H n.m.r.)
(60 mg, 0*10 mmol) and the title compound (R^ 0*4, 50% EtOAc/DCM) as
a white solid (190 mg, 6 8 % corrected yield),
mp. 148-149°C.
^H n.m.r. 5 0*90 and 0*91 (3H, d, 6 Hz, (CH^)_ CH Leu^),
1*36, 1*45 and 1*54 (9H, s, Bu^), 1*5-1*65 (3 H, m, CHg_CH(CH3 )̂  Leu^),
2*95 (2H, m, CH^ Tyri and CH^ Phe^), 3*10 and 3*13 (IH, dd, 13 Hz,
2 Hz, CH2 Tyri and CH^ Phe^), 4*2-4*3 (5H, m, CH^ Glyi, Glyt^, CH 
Leu5), 4*46 (IH, 2t, 8*5 Hz, 5*5 Hz, CH Tyri), 5.95 (IH, br q, CH Phe^), 
5*38 (IH, d, 7 Hz, NH Tyri), 6*81 (IH, d, 8 Hz, NH, Leu^). 7*05-7*25
(9H, ra, aromatic), 7*3 (IH, br t, 4-5 Hz, NH Glyi), 7*43 (IH, br s,
NH Phe4), 9*15 (IH, t, 4-5 Hz, NH GlyfZ).
^^C n.m.r. Ô 22*3 and 22*9 (q, CH 3 Leu^), 25*0 (d, CH(CH 3 ) 2 Leu^)
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27-7, 28-1 and 28-4 (q, (ÇHs)^ C), 37-9, 39-5 and 39-5 (t, ÇHjCHCCHj)^ 
Leu^, CHî Tyr', CH; Phe"), 41-9 (t, CH; Gly^), 48-9 (CH; Glyt^), 51-8, 
54-2 and 56-0 (d, CH T y r \  CH P h e \  ÇHCO 2 C H 3 Leu®), 80-3, 81-8 and 
83*4 (s, (CHs)^ C ), 121-129*5 (aromatic C), 134*2 and 136*6 (s, Phe , 
Tyr^), 150*2 (s, Tyr^), 151*8 (s, C=0, carbonate), 156*8 (s,
C=0, carbamate), 167*0 (s, C=0, ester), 170*7, 171*8 and 172*0 (s,
0=0, amide), 198*5 (s, C=S).
I.R. 3300 (NH), 1760 (0=0, ester, carbonate), 1690 (0=0,
carbamate), 1650 (0=0, amide).
U.V. 264 (E = 1*19 X 10**).
Mass (m/e) (CI), 392 (H-Gly-Phe-Leu-OBu^, 1*4), 279 (H-Phe-Leu-OH or
BOC-Tyr-Glyt+, 48), 260 (279-H20, 43).
Elemental Analysis, Found: C, 60*84; H, 7*51; N, 8*19; S, N/D.
Cale, for CuzHeiNçOioS: C, 60*94; H, 7*38; N, 8*46.
Tyrosyl-thioglycyl-glycyl-phenylalanyl-leucine trifluoroacetate sait
(83)
To a solution of BOC-Tyr(BOC)-G1yt-Gly-Phe-Leu-OBu^ (94) (90 mg, 
0*11 mmol) in dry DCM (2*7 ml) was added anisole (0*10 ml, excess) and 
TFA (0*3 ml) and the mixture stirred at room temperature (1*5 h). The 
solvent was evaporated and ether ( 1 0  ml) added to the liquid residue. 
The slightly coloured (cream) precipitate so formed was separated by 
décantation of the solvent and then washed with a further ether aliquot 
(5 ml). The precipitated product (52 mg) consisted of two major com­
ponents by reverse phase TLC (50:50, MeOH:water) at R^ 0*8 and R^ 0*15. 
The two were separated and purified by medium pressure column chroma­
tography using reverse phase silica.
The lower R^ component after purification afforded a white powder 
(25 mg, 31%) identified as the t-butyl ester (99) of the title
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compound, primarily by n.m.r. (400 MHz).
^H n.m.r. (400 MHz) 6 0*93 and 0-98 (3H, d, 6*5 Hz, (CH3 )z C H ) , 1-48 
(9H, s, t-Bu), 1*62 (2H, m, 9 Hz, 6 Hz, Œ 2 CH M e 2 ), 1*71 (IH, br m,
6*5 Hz, CH CH 2 CH M e 2 ), 2*98 and 2*99 (IH, dd, 14 Hz, 10 Hz and 14 Hz,
9 Hz, CH 2 Tyri CH 2 Phe^), 3*21 and 3*24 (IH, dd, 14 Hz, 4*5 Hz and
14 Hz, 6 Hz, CH 2 Tyr^ and CH 2 Phe**), 4*13 (IH, dd, 9 Hz, 6 Hz, CH),
4*18, 4*23, 4*32 and 4*36 (IH, d, 17 Hz, CH 2 Glyt^ and CHg Glyi), 4 . 3 4
(IH, dd, 9 Hz, 6 Hz, CH), 4*74 (IH, dd, 10 Hz, 4*5 Hz, CH Tyri cH
Phe^), 6*85 and 7*15 (2H, d, 8*5 Hz, Tyri, aromatic), 7*2 -7*3 (5H,
m, aromatic). (Other protons exchanged with solvent, DzO/MeOH-d^.) 
Mass (m/e) (Cl), 392 (Gly-Phe-Leu-OBu^, 9),336 (392-Bu^, 75), 279 
(H-Phe-Leu-OH, 96), 261 (2 7 9 -H 2O, 100).
After a similar purification the higher component (83) (15 mg, 
2 0 %) was obtained as a white powder and identified as the title 
compound.
iH n.m.r. (400 MHz) 6 0*95 and 0*98 (3H, d, 6 Hz, (CH3 ), CH), 1*65
(2H, br t, 7 Hz, CHg CH M e 2 ), 1*72 (IH, br m, 6 Hz, CHg CH M e 2 ), 2*98
and 3*01 (IH, dd, 14 Hz, 9 Hz and 14 Hz, 10 Hz, C H 2 Tyri and CH 2 Phe**),
3*21 and 3*24 (IH, dd, 14 Hz, 6 Hz and 14 Hz, 4*5 Hz, CH 2 Tyri
CH 2 Phe**), 4*11, 4*18, 4*48 and 4*58 (IH, d, 16 Hz, CH 2 Glyt= and
CH 2 GlyS), 4*15 (IH, dd, 9 Hz, 6 Hz, CH Tyri ^H Phe**), 4*35 (IH, t,
7 Hz, CH Leu^), 4*71 (IH, dd, 10 Hz, 4*5 Hz, CH Tyri or CH Phe**), 6*85
and 7*17 (2H, d, 8*5 Hz, Tyri, aromatic), 7*25 (5H, m, aromatic).
(Other protons exchanged with solvent, B^O/MeOH-d^).
Mass (m/e) (FAB+), 572 (M+1, 5*5), 556 (M-NH2 , 1), 538 (5 5 6 -H 2O, 1),
+
336 (Gly-Phe-Leu-OH, 2-5), 279 (H-Phe-Leu-OH, 23), 136 (HzN = 
CHCHzCsH^OH, 64), 120 (HjN = CH CHz Ph, 100), 91 (C7H 7+, 23).
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Elemental Analysis, Found: C, 51*11; H, 6*02; N, 9*87. Calc, for 
C 3 0 H 3 8 N 5O 6SF3 H 2O : C, 51*21; H, 5*69; N, 9*95.
The t-butyl ester (99) could be converted to the title compound 
(83) (50%) under identical conditions except that the reaction was 
stirred for a longer duration ( 6 h ) .
N-Triphenylmethyl-2-aziridine carboxylic acid methyl ester (139)
The title compound®®’®^ was prepared in a three step sequence 
from serine methyl ester hydrochloride salt (136) following the 
procedure®®’®® described for the corresponding 3-methyl derivative 
(140). Crystallization from petroleum ether (60-80) afforded colour­
less crystals. 
mp 106*5 - 108°C
n.m.r. 6 1*4 (IH, dd, 1*5 Hz, 6 Hz, 3H trans), 1*9 (IH, dd,
2*5 Hz, 6 Hz, aH), 2*3 (IH, dd, 1*5 Hz, 2*5 Hz, 3H cis), 3*75
(3H, s, OCH 3 ), 7*2-7 *6 (15H, m, aromatic).
^®C n.m.r. 6 28*6 (t, Ç H 2N ) , 31*7 (d, NÇHCO2 C H 3 ), 51*9 (q, OCH 3 ),
74*4 (s, P h 3 Ç-N), 126*9-129*3 (3C, aromatic), 143*6 (s, Ca aromatic),
171*8 (s, C=0, ester).
I.R. V , 1750 (C=0. ester)  max
Mass (m/e) (Cl), 285 (M-CO2 C H 3 , 7), 243 (Ph3C+, 100)
Elemental Analysis, Found: C, 80*67; H, 6*21; N, 3*81. Calc, for 
C 2 3 H 2 1 NO 2 : C, 80*47; H, 6*12; N, 4*08.
N-[N’-tert-Butoxycarbonylvalyl1-2-aziridine carboxylic acid methyl 
ester (142)
To a solution of Tr-Azy-OMe (139) (1*0 g, 2*9 mmol) in CHCI3 
(4 ml):Me0H (4 ml) was added TFA (4 ml) slowly (0*1 h) dropwise .
The reaction mixture was stirred at room temperature (3 h). The
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slightly coloured (yellow) solution was evaporated to remove solvent 
and then dry ether (5 ml) added and the solution re-evaporated. This 
process was repeated twice more to remove all traces of TFA. The 
crude residue was blown dry (N2 ) overnight and used as follows.
To a cooled (-20°C) solution of BOC-Val-OH (141) (696 mg,
3*2 mmol) in DCM (20 ml) was added DPPCl (70) (758 mg, 3*2 mmol) and 
NMM (0*35 ml, 3*2 mmol) and the mixture stirred (0*3 h ) . A solution of
the crude aziridine in DCM (5 ml) neutralized with NMM (0*35 ml,
3*2 mmol) was then added. The solution was allowed to warm up to room
temperature overnight (16 h). The reaction mixture was evaporated and
taken into EtOAc (50 ml) and washed in the normal way. After drying 
(MgSOit) and evaporation of the organic phase the crude residue was 
subjected to medium pressure column chromatography (5% EtOAc/DCM).
The fractions containing the desired product were combined and 
evaporated giving the title compound as a white solid (340 mg, 39%) 
crystallized from DCM/petroleum ether (40-60) as colourless needles. 
mp 56*5 - 58*0°C
n.m.r. Ô 1*0 (6 H, t, 7 Hz, (CHs)^ CH), 1*4 (9H, s, (CH3 )a C),
2*2 (IH, m, CH Me 2 ), 2*7 (2H, m, CH 2 N), 3*25 (IH, dd, 3 Hz, 5*5 Hz,
NCH), 3*8 (3H, s, OCH3 ), 4*2 (IH, dd, 9 Hz, 4*5 Hz, NH CH), 5*2 (IH, 
br d, 9 Hz, NH).
^®C n.m.r. 6 17*4 and 19*3 (q. Me 2 CH), 28*3 (q. M e 3 C), 30*6 (t,
CH 2 N), 31*6 (d, CH M e 2 ), 34*4 (d, CH N), 52*3 (q, OMe), 60*6 (d, NH 
C H ) , 79*7 (s. M e 3 C^), 155*7 (s, C=0, carbamate), 168*6 (s, C=0, ester), 
182*8 (s, C=0, amide).
I.R. , 3340 (NH), 1750 (C=0, ester), 1705 (C=0, carbamate), 1680 
(C=0, amide).
Mass (m/e) (Cl), 301 (M+1, 0-5), 245 (M-C^He'^, 3-5). 227 (M-C^HeCO'*', 5), 
200 (M-BOG or M-(Azy-OMe), 6 ), 116 (Bu’̂ O-CO-NH''', 40),
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102 (Bu^O-CO'^, 100).
Elemental Analysis, Found: C, 56*02; H, 8*08; N, 9*45. Calc, for 
C 1 4 H 2 4 N 2O 5 : C, 56*00; H, 8*00; N, 9*33.
Also isolated from the reaction mixture by column chromatography 
was a white solid (90 mg, 9%) identified as N-tert-butoxycarbonylvalyl- 
3-chloroalanine (145) from the following data.
n.m.r. 6 1-0 (6 H, t (2d), 6 Hz, (CH,), CH), 1-4 (9H, s, (CH,), C),
2-1 (IH, m, CH Mez), 3-8 (3H, s, OCH 3 ), 3-9 (2H, t (dd), 3-5 Hz, CH;
01), 4-05 (IH, m, CH CH; Cl), 5-0 (IH, m, CH Val^), 5-3 (IH, br d,
9 Hz, NH Val‘), 7-15 (IH, d, 8  Hz, NH).
“ C n.m.r. 6 17-6 and 19-2 (q, Mea CH, 28-3 (q. Me, C), 30-9 (d, CH 
Mea), 44-7 (t, CHa Cl), 52-9 (q, OMe), 53-3 (d, ÇH CHa Cl), 59-6 (d,
CH NH), 80-1 (s. M e 3 C), 155-8 (s, C=0, carbamate), 169-1 (s, C=0, 
ester), 171-9 (s, C=0, amide).
Mass (m/e) (Cl), 337 (M+, 1 ), 309 (M-MeOH, 2), 281 (M-C4H 8+, 9), 237
(M-BOC, 42), 72 (C^HsO'*', 100), 57 (C4H 3+, 73).
Reaction of N-[N’-tert-butoxycarbonylvalyl]-2-aziridine carboxylic 
acid methyl ester (142) with Lawesson's reagent (25)
A suspension of BOC-Val-Azy-OMe (142) (50 mg, 0*17 mmol) and 
Lawesson’s reagent (25) (37 mg, 0*09 mmol) in dry xylene (5 ml) was 
heated at 70-80°C (0*1 h). The resultant solution was cooled to room 
temperature (0*5 h) and the solvent evaporated to give a slightly 
coloured (yellow) oily product. The latter was subjected to medium 
pressure column chromatography (4% EtOAc/DCM). Fractions containing 
the desired product (R^ 0 *4 ) were combined and evaporated to afford 
a slightly coloured oil (10 mg, 18*5%). This product was not stable 
and decomposed in air (2-3 d).
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n.m.r. (60 MHz) 6 1-0 and 1*05 (3H, d, 7 Hz, CH (CH^)z), 1*4 (9H, 
s, t-Bu), 2*2 (~1H, m, CH M e z ) , 2*9 (2H, m, aziridine 3H), 3*35 (IH, 
dd, 3 Hz, 6 Hz, aziridine a H ) , 3*7 (3H, s, OCIia), 4*2 (IH, m, NH C]1 ), 
5*2 ( IH, br d, NH).
Other products were not observed in this reaction although a small 
amount of a component identified as unreacted BOC-Val-Azy-OMe (142)
( ~ 5  mg, 1 0 %) was also isolated from column chromatography.
Reaction of N-[N’-üert-butoxycarbony1valy1 ]-2-aziridine carboxylic 
acid methyl ester (142) with "Belleau’s reagent" (27a)
A solution of BOC-Val-Azy-OMe (142) (155 mg, 0*52 mmol) in THF 
(5 ml) was treated with "Belleau’s reagent" (27a) (150 mg, 0*28 mmol). 
The mixture was stirred at room temperature until none of the starting 
dipeptide (142) remained, as monitored by TLC (35% EtOAc/DCM), and the 
solvent evaporated. The residue was subjected to medium pressure 
column chromatography (40% EtOAc/petroleum ether 40-60) and the 
fractions containing the desired product (R^ 0*5) combined and 
evaporated. This afforded a colourless oil which, after rigorous 
solvent removal, solidified to a white solid ( 1 2 0  mg).
^H n.m.r. (60 MHz). This spectrum was complex and could not be fully 
assigned but contained the following signals; 0*9 (6H, m, (CH%)? CH), 
1 . 4  (9H, s, Bu^), 2*1 (2H, m ) , 3*7 (3H, d, OMe), 7-8 (9-lOH, m,
aromatic).
Mass (m/e) 464 (0*4), 448 (0*4), 331 (2*6), 278 (3), 105 (100), 57 
(C4H 9 , 89).
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Reaction of BOC-Val-Azy-OMe (142) with Phosphorus pentasulphide
A solution of BOC-Val-Azy-OMe (142) (400 mg, 1*33 mmol) in THF 
(10 ml) was treated with phosphorus pentasulphide (P2S 5 ) (327 mg,
1*47 mmol). The suspension was subjected to ultrasonic vibration, 
using an ultrasonic cleaning bath, at 30°C (3*7 h). The mixture was 
evaporated and the residue partitioned between EtOAc (50 ml) and 
aqueous citric acid (5%, 25 ml). The heterogeneous mixture was 
filtered to remove an insoluble white solid. The filtrate was separa­
ted and the organic layer washed with water (3 x 20 ml) before drying 
(MgSOit), filtration and evaporation. The slightly coloured (yellow) 
oily residue was subjected to medium pressure column chromatography 
(40% EtOAc/DCM) and the first few fractions, containing a mixture of 
components combined and evaporated to afford a colourless oil (150 mg).
^H n.m.r. (60 MHz) 6 0*95 and 1*0 (3H, d, 7 Hz, Me? CH), 1*4 (9H, s, 
t-Bu), 3*6 (3H, br s, OCH 3 ) (Other signals comprised several small 
multiplets (br) between 3 and 5 ppm and were unresolved.)
Mass (m/e) (Cl), 335 (11), 317 (37*5), 279 (100), 261 (88*4), 235 (61), 
217 (24).
N-tert-Butoxycarbonyl-valine piperidide (132a)
To a cooled (-20°C) solution of BOC-Val-OH (141) (2*17 g,
10 mmol) in dry DCM (30 ml) was added DPPCl (70) (2 ml, 10*5 mmol) and 
NMM (1*1 ml, 10*1 mmol) and the mixture stirred (0*3 h). Piperidine 
( 2 ml, 2 0  mmol) was added slowly (0 * 2  h) and the reaction mixture 
allowed to warm to room temperature ( 2 h) and stirred for a further 
period (5 h). The solvent was evaporated and the crude residue taken 
into EtOAc and washed in the normal way. After drying (MgSOi*) the 
organic phase was evaporated and subjected to medium pressure column
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chromatography (10% EtOAc/DCM). The fractions containing the desired 
product (R^ 0*3) were combined and evaporated giving the title compound 
as a colourless oil. After several evaporations from ether the oily 
product solidified in air (7 d) to a colourless semi-crystalline 
solid (2*7 g, 95%). 
g g  53-54*5°C
n.m.r. 6 0*9 and 0-95 (3H, d, 8  Hz, (CHa)^ CH), 1-40 (9H, s,
(CH^a)g C), 1*60 (6 H, br s, CH 2 piperidine), 1*9 (IH, m, CIl (€^3 )2 ),
3-5 (4H, br m, CH 2 N), 4*5 (IH, dd, 7 Hz, 8 Hz, CH NH), 5-45 (IH, d,
8 Hz, NH).
 ̂®C n.m.r. 6 17*1 and 19*7 (q, ( ^ 3 ) 2 CH), 24-6. 25*7 and 26*6 (t, 
CH 2 ), 28*4 (q, (CH3 ) 3 C), 31*6 (d, CH ([^3 )2 ), 43*1 and 46*8 (t, CH 2 
N), 5 4 . 7  (d, CH NH), 79*1 (s, Ç  (CH3 )a), 155*9 (s, C=0, carbamate), 
170*2 (s, C=0, amide).
I.R. , 3300 (NH), 1705 (C=0, carbamate), 1625 (C=0, amide).
Mass (m/e) (Cl), 285 (M+1, 42), 229 (M-C^Hg, 100), 185 (M-BOC, 79),
72 (C4H 8O+. 36).
Elemental Analysis, Found: C, 63*59; H, 10*10; N, 10*12. Calc, for 
C 15H 2 8N 2O 3 : C, 63*38; H, 9*86; N, 9*86.
N-tert-Butoxycarbonyl-valine thiopiperidide (132b)
A suspension of BOC-Val-Piperidide (132a) (827 mg, 2*9 mmol) and 
Lawesson's reagent (25) (655 mg, 1 * 6  mmol) in toluene (15 ml) was 
heated at 80°C (4*5 h). The resultant solution was cooled to room 
temperature and evaporated. The crude residue was subejcted to 
medium pressure column chromatography (DCM) and the fractions con­
taining the desired product (132b) (R^ 0*25) combined and evaporated. 
This gave the title compound as a colourless oil (210 mg, 24%). Some 
of the starting piperidide (132a) was also recovered (150 mg, 0*5 mmol)
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by elution with a more polar solvent (5% EtOAc/DCM).
n.m.r. 6 0-95 (6 H, t, 8  Hz, CH Meg), 1*4 (9H, s, t-Bu), 1-75 (6 H, 
br s, CH 2 of piperidine), 2*05 (IH, m, C]1 Mea), 3*9 (2H, br s, CH 2 N), 
4*3 (2H, br m, CH 2 N), 4*6 (IH, dd, 8 Hz, 9*5 Hz, CH NH), 5*7 (IH, 
br d, 9*5 Hz, NH).
^®C n.m.r. 6 17*2 and 19*9 (q, M e 2 CH), 24*4, 25*5 and 27*0 (t, CH 2 ), 
28*4 (q, ^ 3  C), 34*3 (d, CH M e 2 ), 51*3 and 52*1 (t, CH 2 N), 59*2 (d,
CH NH), 79*2 (s. M e 3 C ), 155*5 (s, C=0 carbamate), 202*7 (s, C=S).
Attempted S-methylation of N-tert-butoxycarbonyl-valine thiopiperidide
(132b)42,43
A solution of BOC-Valt-Pip (132b) (230 mg, 0*77 mmol) in dry THF 
(10 ml) was treated with methyl iodide (0*25 ml, 4 mmol) and the 
mixture stirred at room temperature overnight (16 h) in the dark.
The reaction mixture was evaporated to afford a slightly coloured 
(yellow) oil. The ^H n.m.r. (60 MHz) of this material was identical 
in all respects to starting piperidide.
The oil was re-dissolved in dry THF (13 ml) and the solution 
treated with methyl iodide (0*5 ml, 8  mmol) and refluxed (48 h).
After evaporation a coloured (yellow) oil was again obtained. ^H n.m.r 
(60 MHz) of this material was identical with starting material (132b).
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Abstract - N-protected dipeptide esters ha/e been converted into the 
corresponding protected endothiopeptides^^ using Lawesson's reagent,^ 1. 
Methods of amino and carboxyl deprotection, and coupling of the thiopep- 
tides with aunino acids have been defined and used to prepare two examples 
of novel N-protected endothiotripeptide esters with a single thioamide 
link. Possible effects of the thioamide bond on the conformation of the 
dipeptide esters are considered.
Until recently there were very few reports in 
the literature concerning the synthesis of 
endothiopeptides.1 » 3 The introduction of 
Lawesson's reagent by which amides are readily 
converted in high yields into thioamides? has 
given new impetus^&'b to this synthetic object­
ive. We are prompted by these recent disclos- 
ures3 to report our interest in sulphur 
analogues of biologically important peptides.
Our complementary studies in this area led us 
to examine the scope of this reagent and to 
determine whether the existing protection, de­
protection, and coupling procedures used in 
conventional peptide synthesis are generally 
applicable to these new systems.
It has been shown that both the amino and 
carboxyl functions react with Lawesson's 
reagent^ and so N-protected dipeptide esters,
2 were used. The thiopeptides, 3. shown in Table 
1 were readily prepared from the corresponding
peptides, 2  high yields according to the 
generalised equation 1.
The same reaction conditions have been 
employed for each substrate but no difference 
in rate of thionation of the different dip>ep- 
tide amide funtions has been detected, thus it 
is improbable that selective thionation of tri- 
and higher peptides will easily be achieved. 
High resolution mass measurements (Taible 1) 
correspond to the expected molecular formulae; 
the fragmentation patterns conform to those 
previously described. All compounds were 
homogeneous by TLC and NMR.
The NMR, NMR and UV data on these
compounds are presented in Table 2 and the 
linear relationship described by Clausen et al 
whereby 6(C=S)=1.62. 6{C=0)-74.15 used to 
obtain the calculated ^chemical shift values 
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R^OCNHCHCCHCOR^  Eq. 1
t The name endothiopeptide has been used previously for peptides with the thioamide link in the 
backbone . ' ' ̂
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The protective benzyloxycarbony1 (Z)
group was removed from the doubly-protected 
endot h lopept ides , 3. by hydrogen bromide in 
acetic acid at room temperature^ and the tert- 
butoxycarbonyl (Boc) group similarly using tri- 
fluoioacetic acid.^ In each case very good 
yields of N-deprotected compounds were obtained 
in the former as the hydrobromide and in the 
latter as the trifluoroacetate salt.
The NMR spectral date of the N-deprotect- 
compcunds, ^ ate collected in Table 3. Both 
4a and £b have prominent ions in their mass 
spectra at M-81 due to their parent amines. 
Fragmentation in 4a occurs via the loss of 
methanol and then CO and analogously in £b 
where the tropylium ion also figures prominent­
ly. In each case the base peak is at 30 mass 
units [CHj'NHjlî
Attempts to remove the carboxyl protect­
ing groups from the doubly-protected peptide,
3a, selectively using alkaline hydrolysis 
m e t h o d s ^ b  result in deep orange/red coloured 
mixtures (by TLC). Only poor yields of the 
free acid were obtained and so this deprotect­
ion method was not pursued.
Removal of both amino and carboxyl pro­
tecting groups of _3b and _3d by HBr/AcOH 
at 60® gave the endothiopeptides, repre­
senting for the first time the preparation of 
totally deprotected systems.
Surprisingly, double deprotection of the 
ester takes place much more rapidly than 2£ 
in the presence of hydrogen bromide in acetic 
acid.
The Ĥ- and ^^C- NMR spectra of S are 
consistent with those expected for the endothio- 
dipept ides (see Table 3).
In the case of 5d and the main
differ.ence in the '^C-NMR spectrum is the 
absencce of resonance at about 52.0 ppm for 5d, 
the chiaracteristic position of the methoxyl 
carbon . Spectroscopic data were in accord 
with e:ndothioaminocarboxylic acids. The mass 
spectr a of these compounds give highest mass 
ions of 100 mass units (-HBr-HjO) lower than 
that expected and may be due to ions correspond­







In an initial study of the conformational 
consequences of the introduction of the thio­
amide group into petides, differential nOe 
spectra were taken on compounds 2e^ and 3e.
Each spectrum was consistent with favoured 
conformations and J_0 resulting from hydrogen 
bonding between the amide N-H and carbamate 
carbonyl oxygen atom. In the case of the thio­
amide 3e a strong (33%) enhancement of the 
methylene protons was observed when the Ala- 
methyl group was continuously irradiated.
There was no corresponding enhancement in 2e, 
but instead an enhancement (14%) of the signal 
due to the carbamate N-H proton when the methy­
lene protons were irradiated. These observa­
tions may correspond to different preferred 
conformations about the carbamate C-0 bond.
The thioamide proton is more acidic than 
the amide one and this could bring about 





depletion in electron density in the carbamate 
C=0 might result in more double bond character 
in its C-0 bond favouring the conformation 
about the carbamate bond shown in In
conclusion, difference nOe at 400 MHz indicates 
a significantly populated conformation (10) 
for the endothiopeptide 3e.
It has been reported that thionation of 
peptides with Lawesson's reagent takes place 
with no appreciable degree of racemization.
This claim is based on a comparison of optical 
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esters, obtained by dethiation of the corres­
ponding endothiopeptides prepared using the 
reagent, with samples of original starting 
N-protected dipeptide esters. Recent studies' 
have shewn that N-alkyloxycarbonyl protected 
peptides are much more resistant to racemiz­
ation than N-acyl protected peptides under 
reaction conditions appropriate for new peptide 
bond formation. As a consequence of the above 
we expected our peptides to retain their stereo 
-chemistry and used high resolution (400 MHz) 
1h-NMR spectroscopy to confirm this expectation 
as follDws. The methyl ester 3e.' Z-Alat-Ala- 
OMe contains two chiral centres and so racemiz­
ation at either centre would give rise to a 
mixture of diastereoisomers. The 1h-NMR spec­
trum shows overlapping doublets (1.46 and 1.47, 
3h , J=7Hz) due to the methyl groups and two 
pentets (4.60 and 5.05, IH, J=7Hz) due to the 
two me thine protons further coupied (J=7Hz) to 
N-H. Decoupling from N-H reduced each pentet 
to a quartet. The  ̂"̂ C-NMR spectrum (Taible 2) 
contains thirteen lines only. The foregoing 
data can only be explained in terms of one 
diastereoisoroer. The high signal to noise ratio 
and the sharpness of the signals in the ^H-NMR 
spectrum would allow the detection of isomeric 
impurities down to perhaps 2-3%; only signals 
due to 3ê were present in its NMR spectra.
The feasibility of synthesising higher 
endothiopeptides by coupling with N-protected 
amino acids at the terminal amino group was 
confirmed by the reaction of the hydrobromide 
salt of the endothiopeptide ester 4a with 
Z-Ala-OH to give Z-Ala-Glyt-Gly-OMe 6a. This 
preparation was carried out using standard 
conditions^ whereby the salt was neutralised 
with triethylamine and the coupling promoted 
by dicyclohexylcarbodiimide (DDC). This is 
represented in Equation 3.
Z-AI«-OH + HBr.Glyt-Gly-OMt 4a — -
Z-Ala - Glyt - Gly-OMe 6a .... Eq . 3
Having branched from the aunino terminal, 
we investigated the alternative coupling at 
the C-terminal end of an N-protected endothio­
peptide ester. This was achieved by utilizing 
a phenyl ester protecting group (first proposed 
by Galpin et al^). Thus Z-Glyt-Gly-Gly-OMe, 6b, 
has been prepared from Z-Glyt-Gly-OPh, 3^, and 
glycine methyl ester according to Equation 4.
Z - G l y t - G l y - O P h  4- H C I . G I y - O M *
l>f




Attempts to improve the relatively pxoor yield 
(47%) using an ester group which was more 
susceptible to nucleophilic displacement, eg 
£-nitrophenyl, by a free euzino group have been 
unsuccessful. Thionation of Z-Gly-Gly-OnPh 
with 2 afforded several inseparable, unidenti­
fied products. Significantly p-nitrophenol 
was also obtained from the reaction so that 
thionation possibly led to an intramolecular 
cyclization whereby the nitrophenate anion 
was displaced by the thiono group.
To sum up, we have extended the range of 
doubly protected dipeptide substrates for which 
thionation using Lawesson's reagent proceeds in 
high yield, defined a major conformer of an 
N-Z-endothiopeptide ester and shown that the 
conventional peptide deprotection and coupling 
procedures are applicable to the synthesis of 
endothiopeptides from smaller units containing 
the thioamide bond.
EXPERIMENTAL
The abbreviations used are those in common 
use and all the amino-acids have the L-configur- 
ation. Other abbreviations are as follows*
TEA. triethylamine; DCM, dichloromethane;
DCC, N,N'-dicyclohexylcarbodiimide; nPh, 4- 
nitrophenyl; DCU, N,N'-dicyclohexylureaIPA, 
isopropanol. Silica gel 60 (Merck No: 7747) 
was used. The ^H-NMR spectra were determined at 
100 MHz using a Jeol PSIOO spectrometer, unless 
otherwise stated, and '^C-NMR spectra at 
22.5 MHz using a Jeol FX90Ç spectrometer. The 
H-NMR spectra of 2e_ and were determined on 
A Brucker WH400 with a pulse length of 4us at 
an angle of 45-50°. The differential nOe 
spectra were run at 310 K with GM (LB0.85) 
with 40 scans accumulated for each spectrum.
TetramethyIsilane was used as internal standard. 
Mass spectra were recorded by PCMU (Harwell) 
at 70eV. Lawesson's reagent, 2» was either 
prepared by the literature procedure^ or a 
commercial sample (Aldrich Ltd) was used.
Z-Ala-Ala-OMe, 2£> was prepared from the
9free a(̂ id by a standard estérification method 
(SOCl^/MeOH). Z-Gly-Gly-OPh, 2f, was prepared 
using the method of Galpin et aj_̂ . from the free 
acid (Z-Gly-Gly-OH).
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Preparation of N-protected endothiopeptide 
esters, 3.
Z-Phet-Gly-OMe, 3c, Z-Phe-Gly-OMe, 2c 
(460 mg, 1.24 mM) and Lawesson's reagent , 2 
(250 mg, 0.62 mM) were heated together at 95- 
100° in sodium dried toluene (20 cm^) for 2 hr. 
The reaction was followed by TLC on silica gel 
00%, ethyl acetate-dichloromethane). Evapora­
tion 2£ vacuo gave a pale yellow oil which 
was chromatographed (10% EtOAc-DCM, flash 
chromatography) giving 3c (400 mg, 1.04 mM, 84%), 
mpt: 68-69.5°C as a white solid which could
be recrystallized from MeOH/H^O. 3d And 3£ 
were obtained as colourless oils.
Removal of the Z-group from the N-Z-endothiopep­
tide esters 3.
Br~H~"̂ -Glyt-Gly-QMe, 4a. 3a, (640 mg. 2.2 
mM) was stirred for 1 hour at 20°C in HBr/Ac(OH 
(48% w/v, 10 cm^) in a flask fitted with a CaCl^ 
drying tube. Dry ether (50 cm^) was then added 
to precipitate more white solid and the whole 
then filtered and the residue washed with ether. 
This gave 4a (500 mg, 2.1 mM, 95% yield) as a 
white solid, mpt: 171-173°C (decomp). (Found: 
M*'-HBr, 162.0475. C^H^^NgOgS requires 
162.0461).
Simultaneous removal of the amino and carboxyl- 
protective groups.
Br~H2~^-Glyt-Gly-OH, 5a. Z-Glyt-Gly-OMe 
3a (190 mg, 0.64 mM) and HBr/AcC*i (48% w/v, 10 
cm3) were stirred at 55°C in a flask fitted 
with a CaCl2 drying tube and a reflux condenser 
for 6 hr. (1.5 hr. for 3d). On cooling, ether 
(50 cm^) was added to precipitate a white solid* 
which! was filtered and washed with a small 
amounit of ether. This gave 5a (140 mg, 0.61 mM, 
95% yield) as a slightly coloured solid, n^t: 
91-94°C. (Found: M*-HBr-H20, 130.0201.
C4H&W2O2S requires 130.0200).
Removal of the Boc-group from 3.
TFA'H^^-Glyt-Gly-OBzl, 4b, Boc-Glyt-Gly- 
OBzl, 2^ (169 mg, 0.5 mM) was stirred in a 
solution of 90% TFA (10 cm-̂ ) at RT for 0.5 hr. 
The excess TFA was removed by toluene azeotrope 
(2 X 20 cm^) in vacuo to give a viscous oil 
which solidified on standing to an off-white 
solid, 4b, (140 mg, 0.47 mM, 94% yield), mpt: 
129-131°C (decomp). (Found: M*-TFA, 238.0769 
C11H 14N2O2S requires 238.0773).
Preparation of N-Z-endothiotripeptide esters, 6
Z-Ala-Glyt-Gly-OMe, 6a. A suspension of 
the salt, 4a (242 mg, 1.0 mM) and N-Benzyloxy- 
carbonylalanine (223 mg, 1.0 mM) in DCM (5 cm^) 
was added over 5 min. and the suspension stirr­
ed for a further 5 min. and then allowed to 
reach RT. A solution of DCC (206 mg, 1 mM) in 
DCM (10 cm3) was added slowly over 1.25 hr.
After stirring at RT for a further 20 hr., the 
reaction mixture was filtered to remove DCU 
and the solvent evaporated under vacuum. The 
residue was subjected to medium pressure column 
chromatography (5% EtOH in CHCl^), giving a 
white crystalline solid, 6a, (290 mg, 0.79 mM, 
79% yield, mpt: 108-109°C.
Z-Glyt-Gly-Cly-OMe, 6b. Z-Glyt-Gly-OPh,3f, 
(171 mg, 0.5 mM), glycine methyl ester hydro 
-chloride (63 mg, 0.5 mM) and TEA (51 mg, 1 
equiv) were heated to reflux in IPA (25 cm^) 
for 8.5 hr. (No apparent reaction occurred 
at 20°C). After cooling, the solvent was evap­
orated in vacuo and the orange-brown residue 
subjected to medium pressure column chromato­
graphy (30% EtOAc/DCM) to remove impurities.
This gave 6b as a white solid (83 mg, 0.24 mM, 
47% yield), mpt: 130.5-132.5°C.
*For the deprotection of Z-Ilet-Gly-OMe, M.' & 
reaction time of 1.5 hr at 20°C was sufficient. 
Addition of ether did not precipitate the 
hydrobromide 5d but the ether layer was extract­
ed with H2O (2 X 50 cm^) and the aqueous ext­
ract evaporated under vacuum to give a pale 
orange solid (75 mg, 0.25 mM, 83% yield), mpt: 
175-179°C (decomp.)
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